Accepted Manuscript

Association between vitamin D status and asthma control: a meta-analysis of randomized trials

Mingming Wang, Meicen Liu, Cairu Wang, Yue Xiao, Tong An, Meijuan Zou, Gang Cheng

PII: S0954-6111(19)30061-7

DOI: https://doi.org/10.1016/j.rmed.2019.02.016

Reference: YRMED 5640

To appear in: Respiratory Medicine

Received Date: 17 September 2018

Revised Date: 10 February 2019

Accepted Date: 15 February 2019

Please cite this article as: Wang M, Liu M, Wang C, Xiao Y, An T, Zou M, Cheng G, Association between vitamin D status and asthma control: a meta-analysis of randomized trials, *Respiratory Medicine*, https://doi.org/10.1016/j.rmed.2019.02.016.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Association between vitamin D status and asthma control: a meta-analysis of randomized trials

Mingming Wang ^a, Meicen Liu ^b, Cairu Wang ^a, Yue Xiao ^a, Tong An ^a, Meijuan Zou ^c, Gang Cheng ^c ^a School of Life Sciences and Biopharmaceutis, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, China. ^b Department of Respiratory, General Hospital of Shenyang Military Area, Shenhe District, Shenyang 110016, Liaoning, China. ^c School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, Liaoning, China

Abstract

Background: There is a controversy in terms of the efficacy of vitamin D supplementation in improving asthma symptom control. Moreover, whether there is a difference in the treatment effect with respect to baseline vitamin D status remains unknown. This meta-analysis was to assess the correlations of vitamin D status with asthma-related respiratory outcomes.

Methods: PubMed, EMBASE, and Cochrane Library were searched for randomized controlled trials of vitamin D supplementation in patients with asthma. Primary outcomes were the rate of asthma exacerbation and predicted percentage of forced expiratory volume in first second (FEV₁%). Secondary outcomes were asthma control test (ACT) scores, fractional exhaled nitric oxide (FeNO), interleukin-10 (IL-10) and adverse events.

Results: A total of 14 randomized controlled trials (1421 participants) fulfilled the inclusion. Vitamin D supplementation was associated with a significant reduction in the rate of asthma exacerbation by 27% (RR: 0.73 95%Cl (0.58-0.92)). In subgroup analysis, the protective effect of exacerbation was restricted in patients with vitamin D insufficiency (vitamin D < 30ng/ml) (RR: 0.76, 95%Cl (0.61-0.95)). An improvement of FEV₁% was demonstrated in patients with vitamin D insufficiency and air limitation (FEV₁% < 80%) (MD: 8.3, 95%Cl (5.95-10.64). No significant difference was observed in ACT scores, FeNO, IL-10 and adverse events.

Conclusions: Vitamin D supplementation reduced the rate of asthma exacerbation, especially in patients with vitamin D insufficiency. Additionally, the benefit of vitamin D had a positive effect on pulmonary function in patients with air limitation and vitamin D insufficiency.

Keywords: Asthma; Vitamin D; Treatment; Meta-analysis; RCTs.

Abbreviations: $FEV_1\%$ = predicted percentage of forced expiratory volume in first second, ACT = asthma control test, IL-10 = interleukin-10, FeNO = fractional exhaled nitric oxide, 25(OH)D = 25-hydroxyvitamin D, CI = confidence interval, MD = mean differences, SMD = standardized mean differences, RR = risk ratios.

1. Introduction

Asthma is a heterogeneous disease and characterized by chronic airway inflammation, which can be control [1]. However, current asthma management remains imperfect that substantial proportion of patients do not achieve optimal asthma control despite high-dose treatment [2]. Recently, multiple epidemiological studies have identified strong associations between vitamin D insufficiency (25-hydroxyvitamin D (25(OH)D) < 30ng/ml) and increased asthma incidence, especially in patients with severe and uncontrolled asthma [3-5]. This may explain by that, vitamin D plays a key role in modulating the immune response and showing anti-inflammatory effects [3,6-9]. Thus, there has been enormous interest in the use of vitamin D as a potential therapeutic option.

The evidence-base increasingly supports vitamin D supplementation being a safe, practical and beneficial part of the comprehensive management of asthma [10]. Nevertheless, a recent review by Hall et al. [11] indicated that the positive effect of vitamin D in asthma control remained controversial. Moreover, randomized controlled trials (RCTs) published recently have examined the potential contribution caused by vitamin D supplementation to asthma susceptibility. One study [12] indicated that 4-month vitamin D supplementation was associated with an improvement in pulmonary function regardless of vitamin D status, whereas other studies [13,14] showed a negative effect on it. In addition, Musharraf et al. [15] reported that vitamin D supplementation was efficacious in the prevention of asthma exacerbation, while two studies [16-17]

reported the inconsistent results. Therefore, the effect of vitamin D supplementation on patients with bronchial asthma is still controversial.

To date, a total of six aggregate data meta-analyses [18-23] have been conducted with inconsistent results. However, few systematic reviews have examined the role of vitamin D on pulmonary function, and the question of whether vitamin D insufficiency is a risk factor for asthma needs to be clarified. Additional five RCTs [12-15,17] have been published since the most recent meta-analysis. In consequence, the main goal of our meta-analysis was to synthesize the evidence to justify whether the recently published RCTs would alter previous conclusions and to sort out causal relationships between baseline vitamin D status and asthma-related outcomes.

2. Material and methods

2.1. Search Strategies

The recommendations on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were regarded as a guideline to perform our meta-analysis [24]. Our protocol was registered in PROSPERO website in April 2018 (CRD42018094893). We performed a comprehensive search in the databases PubMed, EMBASE, Cochrane Library and Clinical Studies.gov using following medical subject heading (MeSH) and free-text terms: "Vitamin D" or "25-hydroxyvitamin D (25(OH)D)" or "Vitamin D-3" or "25-hydroxyvitamin D" or "Cholecalciferol" and "Asthma" or "Bronchial Asthma". Publication type was limited in RCTs. The databases were searched from the inception to the end of March 2018. In addition, a manual search was conducted by searching reference of former meta-analyses and relevant studies, which were not identified in our electronic search. There was no limitation to language.

2.2. Study selection

Two reviewers screened the records independently. Inclusion criteria were listed as following: (1) RCTs; (2) participants with diagnosed asthma; (3) intervention was vitamin D, regardless of the drug names, doses, and administration routines, or as an adjunct to other forms of asthma treatment; (4) outcomes were reported in predicted percentage of forced expiratory volume in first second (FEV₁%), the rate of asthma exacerbation, fractional exhaled nitric oxide (FeNO), asthma control test (ACT) scores, interleukin-10 (IL-10) and the rate of adverse events. Exclusion criteria were: (1) non-RCTs; (2) population of studies was pregnant; (3) the dosing regimen included the fixed administration of another drug or vitamin D without an appropriate control arm; (4) studies only with abstract. The final inclusion was obtained by discussion.

2.3. Data extraction

The following information was screened closely and extracted by two investigators (MMW and CRW) independently to a standardized collection form which we had been made before. A third (YX) reviewer made the final decision when disagreements occurred. Data were collected from the included studies as follows: name of the first author, publication year, country of origin, number of the participants in each trial, details of the intervention treatment, basic characteristics of included patients. Outcomes extracted included FEV₁%, the rate of asthma exacerbation, FeNO, ACT scores, IL-10 and the rate of adverse events. When essential data were not reported, we communicated with the original author of the study to get the desired data. Besides, missing data were also collected in ClinicalStudies.gov when we got the NCT number.

2.4. Outcomes

Primary outcomes were FEV₁% and the rate of asthma exacerbation. FEV₁% was calculated as a change from baseline. Definition of asthma exacerbation differed among studies. Thus, our group utilized the variable definitions reported in primary publications in our meta-analysis. It was defined as an increase in symptoms of shortness of breath, cough, wheezing or chest tightness and progressive decrease in pulmonary function, or require a change in treatment (including short-acting β 2-agonists, antibiotics or oral corticosteroids). Acute-care visit was reported in

one trial [16] which was also considered asthma exacerbation.

Second outcomes were FeNO, ACT scores, IL-10 and the rate of adverse events. The outcomes of FeNO, ACT scores, and IL-10 were also calculated as the change from baseline. ACT scores was defined by GINA [1], and consisted of day-time and night-time symptom control, rescue use of relievers and activity limitations. The following factors were considered as adverse events: hypercalcemic, nephrolithiasis, or urine calcium after vitamin D supplementation.

2.5. Quality assessment

Two reviewers independently evaluated the quality of each selected study using the Cochrane collaboration tools in following seven aspects: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other forms of bias. Moreover, the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was used to assess the quality of each endpoint.

2.6. Statistical Analysis

The statistical analysis was performed with the RevMan software [Review Manager (RevMan). Version 5.2, The Cochrane Collaboration, Copenhagen, Denmark] and the Stata 12.0 software (Statacorp LP, College Station, Texas, USA). Due to studies differed in the mixes of interventions and participants, a random-effect model was conducted to perform the statistical analysis. When data from 3 or more studies were available, outcomes were pooled using mean differences (MD) and standardized mean differences (SMD) (inverse variance method) for continuous variable or risk ratios (RR) (Mantel–Haenszel method) for dichotomous variables. Besides, change between baseline and the longest follow-up duration was conducted to avoid the disturbance of baseline's unbalance for continuous outcomes. Mann–Whitney U-tests was used to conduct statistical analyses, and a two-sided P-value of < 0.05 was considered statistically significant. Heterogeneity among the studies was assessed by Cochran's Q-test, and P < 0.10 was considered statistically significant. Furthermore, the I² statistic was used to calculate the degree of heterogeneity between included studies. I² values of 25%, 50%, and 75% were considered low, moderate, and high heterogeneity [25]. Moreover, prespecified subgroup analyses were stratified by baseline of FEV₁%, 25(OH)D level, co-medication, age (children or adults), dose and duration of vitamin D treatment. And these were conducted to explore the influence and heterogeneity in each outcome. Potential publication bias was failed to perform using funnel plot as each outcome did not reach ten studies. Sensitivity analyses were performed to examine robustness of our results by omitting one study and analyzing the remainders in each turn.

3. Results

3.1. Study Selection

We identified 501 studies using our search strategy. A total of 129 duplicate studies were removed. After titles and abstracts screening, 58 potentially relevant studies were identified. And after reviewing the full-text, 14 studies [12-17,26–33] met our inclusion criteria. A flow chart showing the study selection is presented in Fig. 1.




Figure 1 Flowchart for identification of studies used.

3.2. Study Characteristics

The characteristics of the included studies and participants are listed in Table 1 and 2. A total of 1421 participants (711 intervention group and 710 control group) were enrolled. Among fourteen included studies, clinical features of patients were reported in eleven studies of which eight studies [12,14,17,26,29,30-32] described as stable asthma, one [16] as viral-induced asthma, one [28] as nonatopic asthma and one [33] as IgE-dependent asthma. Nine studies [12,14,15,17,26-28,30,32] were conducted in adults, while five [13,16,29,31,33] studies were in children. Regarding the intervention method, four studies [16,17,27,29] compared vitamin D to placebo as a treatment individually, while other studies received vitamin D as an adjunct treatment. With respect to the baseline 25(OH)D level, eleven studies were vitamin D insufficiency [12,13,15-17,26-29,30,32], while two studies were vitamin D sufficiency (25(OH)D > 30ng/ml) [31,33].

						Intervention			
Author Year	Country	N	participants	Drug	Dose	Co-intervention	Duration (mo)	Follow-up (mo)	Outcomes
Ali2017[12]	Egypt	60	Intermittent to severe persistent asthma	ALF	lmg/d	Intermittent: inhaler 100µg salbutamol Moderate: 12 mg formoterol/ 400 mg theophylline, twice daily severe asthma (>50%): high dose beclomethasone	4	1, 2, 3, 4	FEV1%, AdE
Musharraf 2017[15]	Pakistan	80	Asthma Diagnosed for ≥ 1 year with VD < 30 ng/ml.	VD	50,000IU/2w	ICS (Salmeterol/fluticasone 25/250µg twice daily) + Montelukast 10mg	3	3	AE
ABBAS2017[26]	Iraq	44	Asthma	VD	2000IU/d	Conventional therapy (no description)	3	3	FEV ₁ %, IL-10
Rubén2017[17]	Spain	106	Asthma with VD < 30 ng/ml.	CAL	16,000IU/w	None	6	6	AE, ACT
Jensen2016[16]	Canada	22	Viral-induced asthma	VD	100,000 IU	Vitamin D ₃ 400IU/d	6	0.3, 3, 6	AE, AdE,
Kerley2016[13]	Ireland	39	Uncontrolled asthma	VD	2000IU/d	Conventional therapy (no description)	3.75	3.75	FEV ₁ %, ACT, IL-10, AdE
Martineau2015[27]	UK	250	Asthma treated with ICS	VD	120000 IU/2mo	None	12	2, 6, 12	FEV1%, ACT, FeNO, AE
de Groot2015[28]	Netherlands	44	Nonatopic asthma	VD	400,000 IU	Conventional therapy (no description)	1.5	0.25, 1.5	FEV ₁ %, FeNO _. AdE
Nageswari2015 [14]	India	141	Severe persistent asthma	VD	1000 IU/d	ICS (budesonide 800µg + formoterol 24µg) /d	6	1, 2, 3, 4, 5, 6	AdE
Castro2014[32]	US	408	Asthma with VD < 30 ng/ml	VD	100000 IU once then 4000 IU/d	Inhaled ciclesonide 320µg/d + levalbuterol	7	7	AE, AdE
Yoseph2014[29]	Israel	38	Mild asthma with VD < 30	VD	14,000 IU/w	None	1.5	1.5	IL-10, FeNO

Arshi2014[30]	Iran	130	Mild to moderate persistent asthma	VD	100000IU once then 50000IU/w	ICS (budesonide/budesonide+ formoterol)	6	2, 6	FEV ₁ %, AE,
M-:-1-2011[21]	Delevel	49	Newly diagnosed asthma and	VD	500 H1/4		<i>c</i>	2.4.6	
Majak2011[31]	Poland	48	sensitive only to house dust mites	VD	500 IU/d	Inhaled budesonide 800µg/d	6	2 ,4, 6	FEV ₁ %, AE,
			IgE - dependent asthma with regular symptoms requiring long			S			
Majak2009[33]	Poland	36	- term treatment with ICSs, and	VD	1000IU/d	prednisone 20mg	3,12	3, 12	FEV ₁ %, IL-10
			a disease duration of at least 2						
			years.						

N = number; mo = month; ALF = alfacalcidol; FEV1% = predicted percentage of forced expiratory volume in first second; AdE = adverse events; w = week; VD = vitamin D; ICS = inhaled corticosteroids; AE = asthma exacerbation; IL-10 = 4

interleukin-10; CAL= calcifediol; ACT = asthma control test; FeNO = fractional exhaled nitric oxide.

ng/ml

Table 1 Details of included studies.

	Age	(years)		FEV	1%	FeNC	(ppb)	ACT	Scores	IL-10	(pg/ml)	25(OH)	D (ng/ml)
Author Year	Mear	n (SD)	Sex (Female%)	Mean	(SD)	Mear	1 (SD)	Mear	(SD)	Mea	n (SD)	Mear	n (SD)
	Ι	С		I	С	Ι	С	Ι	С	I	С	Ι	С
Ali2017[12]	43(10.25)	48(11.25)	68.3	57(20.25)	57(20.25)	NM	NM	NM	NM	NM	NM	18(10.33)	18.5(12.8)
Musharraf2017 [15]	29.70(7.74)	29.43(8.47)	42.5	NM	NM	NM	NM	NM	NM	NM	NM	<30	<30
ABBAS2017[26]	41.4 (13.6)	40.75(17.31)	75.0	43.92(20.36)	50.90(16.04)	NM	NM	NM	NM	37.0(8.64)	29.5(5.17)	8.90(6.82)	6.33(4.64)

Rubén2017[17]	54.57(15.83)	56.61(15.00)	77.7	NM	NM	NM	NM	17.71(4.54)	19.02(4.59)	NM	NM	<30	<30
												24.86	27.27
Jensen2016[16]	2.2 (1.19)	3.1 (1.33)	63.6	NM	NM	NM	NM	NM	NM	NM	NM	(2.51)	(2.51)
Kerley2016[13]	10(4.44)	7(2.22)	38.5	105(16.3)	96 (10.37)	NM	NM	19(2.96)	17(3.48)	111	110	20.45	20.45
										(27.41)	(47.41)	(7.43)	(8.92)
Martineau2015[27]	49.4(14.8)	46.4 (13.8)	56.4	82.0 (18.7)	81.0 (20.4)	38.1(29.1)	37.0(26.0)	19.2(3.9)	18.9 (3.9)	NM	NM	19.97	19.81
							~					(10.1) 24.06	(9.7) 22.85
de Groot2015[28]	59(9.7)	53.6(16.7)	40.9	99.1(15.7)	97.6(18.1)	24(12.59)	33(38.52)	NM	NM	NM	NM	(9.27)	(8.91)
Nageswari2015 [14]	58.46(8.6)	57.18(9.2)	52.1	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM
Castro2014[32]	39.9(13.1)	39.5(12.7)	68.1	80.7(13.8)	80.5 (14.2)	NM	NM	NM	NM	NM	NM	19	18.8
	,					Y						(10.37)	(11.85)
Yoseph2014[29]	13.5(3.6)	12.4(3.6)	36.8	NM	NM	36.6(39.1)	58.6(54.7)	NM	NM	0.95(0.19)	0.96(0.19)	20.8(6.5)	20.0(7.1)
												23.82	24.02
Arshi2014[30]	24.40(9.63)	28.64(9.78)	60.8	69.1(9.39)	71.2(7.46)	NM	NM	NM	NM	NM	NM	(16.33)	(16.45)
					Q (36.1	35.1
Majak2011[31]	10.8 (3.2)	11.1 (3.3)	33.3	94.4(13)	98.7(12)	NM	NM	NM	NM	NM	NM	(13.9)	(16.9)
Majak2009[33]	6-12	6-12	38.9	95.2(4.8)	93.4(3.2)	NM	NM	NM	NM	80.0(20.0)	75.3(25.9)	32.0(3.1)	31.3(3.4)

FEV₁% = predicted percentage of forced expiratory volume in first second; FeNO = fraction of exhaled nitric oxide; ACT = asthma control test; IL-10 = interleukin-10; 25(OH)D = 25-hydroxyvitamin D; SD = standard derivation; NM = not mentioned.

 Table 2
 Baseline characteristics of patients in the 14 studies included.

3.3. Quality assessment

The risk-of-bias assessment results are shown in Fig.2. Eight studies [12,14-16, 27, 31-33] described the random sequence generation (e.g., a computer-generated random list, randomization table, random allocation software, a computer-generated allocation schedule) and were regarded as a low risk of bias. However, six [13,17,26,28-30] studies were deemed to have an unclear risk of bias for this domain because there was no description in these studies. Three studies [14,16,28] stated the allocation concealment process and eleven study [12,13,15,17,26,27,29-33] was considered as unclear risk of bias, because we were unclear whether the envelopes were concealed. For blinding of participants and personnel and outcome assessment, two studies [26,30] were open-label and there was no description in five studies [13,15,26,29,31]. However, we thought the endpoints were not affected by a lack of blinding. Thus, these seven studies were defined as a low risk of bias. In the domain of incomplete outcome data, one [13] had an unclear risk of bias because of a high rate of loss. Meanwhile, in the domain of other biases, all the studies were deemed to have a low risk except for three studies [15,29,30]. In the domain of selective reporting, all the studies were deemed to have a low risk of bias. The evidence classification results, summarized from the GRADE evidence profile assessed by the GRADEpro software, are presented in Table 3. The associated quality of evidence was rated as very low or low due to risk of bias, heterogeneity and imprecision. Consequently, the results should be interpreted cautiously.

Figure 2	Risk of bias graph for included studies.
----------	--

Outcome	Study	Risk of	Inconsistency	Indirectness	Imprecision	Publication bias	Quality of
Outcome	design	bias	Inconsistency	Indirectiess	Imprecision	Publication bias	evidence
FEV ₁ %	RCT	Serious ¹	Very serious ²	No serious	Serious ³	Serious ⁴	Very Low
Subgroups:							
А	RCT	Serious ¹	No serious	No serious	Serious ³	No Serious	Low
В	RCT	Serious ¹	Serious ²	No serious	Serious ³	No Serious	Low
С	RCT	Serious ¹	No serious	No serious	Serious ³	No Serious	Low
Adults	RCT	Serious ¹	Serious ²	No serious	serious ³	No Serious	Low
Children	RCT	Serious ¹	Serious ²	No serious	Very serious ³	Serious	Very Low
Exacerbation	RCT	Serious ¹	No serious	No serious	Serious ³	Serious ⁴	Very Low
Subgroups:							
D	RCT	Serious ¹	No serious	No serious	Serious ³	No Serious	Low
Е	RCT	Serious ¹	No serious	No serious	Serious ³	Serious ⁴	Very Low
Adults	RCT	Serious ¹	No serious	No serious	Serious ³	No Serious	Low
Children	RCT	Serious ¹	Serious ²	No serious	Very serious ³	Serious ⁴	Very Low
ACT scores	RCT	Serious ¹	Very serious ²	No serious	Very serious ³	No Serious	Very Low
FeNO	RCT	Serious ¹	No serious	No serious	Very serious ³	No Serious	Very Low
IL-10	RCT	Serious ¹	Very serious ²	No serious	Very serious ³	No Serious	Very Low
Adverse events	RCT	Serious ¹	No serious	No serious	Very serious ³	No Serious	Very Low

FEV₁% = predicted percentage of forced expiratory volume in first second; RCT = randomized controlled trials; VD = vitamin D; ACT = asthma control test;

FeNO = fractional exhaled nitric oxide; IL-10 = interleukin-10; A = subgroup of patients with air limitation and vitamin D insufficiency; B = subgroup of patients

without air limitation and vitamin D insufficiency; C = subgroup of patients without air limitation and vitamin D sufficiency; D = subgroup of patients with

vitamin D insufficiency; E = subgroup of patients with vitamin D sufficiency.

¹ blinding method and selective reporting and other types of some included trials were not offered.

² Inconsistency were reported by moderate to high heterogeneity.

³ The total sample size is much less than OIS and the overall number of events was less than 300.

⁴ Publication bias were reported by incomplete outcome data.

 Table 3
 GRADE assessment of the quality of evidence for endpoints.

3.4. Clinical results

3.4.1. Pulmonary function

Of fourteen studies, eight studies [12,13,26-28,30,31,33] provided data on respiratory function. We demonstrated that there was no significant difference between vitamin D supplementation and placebo (MD: 0.67 95% Cl (-3.83, 5.16)), but with a high heterogeneity ($P < 0.00001 I^2 = 86\%$) (Fig. 3A).

Pre-specified subgroup analyses were conducted to identify the influence of outcomes and possible sources of heterogeneity. Vitamin D supplementation was associated with a significant improvement of $FEV_1\%$ in patients with vitamin D insufficiency and airflow limitation (baseline $FEV_1\% < 80\%$) (MD: 8.30 95%Cl (5.95, 10.64), without heterogeneity (P = 0.40, I² = 0)) (Fig. 3A). No such protective effect was observed among patients without airflow limitation (Fig. 3). Vitamin D supplementation was associated with the $FEV_1\%$ improvement in adults (MD: 4.65 95%Cl (0.02, 9.28)) but with a high heterogeneity (P=0.006 I² = 72%), no such protective effect was seen in children. There was no significant association within subgroups based on different doses or treatment duration of vitamin D, but with a high heterogeneity in the subgroups




Figure 3 Pooled mean difference for the FEV1% with 95% confidence intervals of eligible studies comparing vitamin D supplement vs placebo.

A	Exp	eriment	d	c	Iontrol			Mean Ofference		Mean D	Merence		В	Expe	intental			Sontre			Mean Difference	Man	s Difference	
tudy or Subgroup	Mean	SD	Total	Mean	50	Total.	Weight	IV. Random, 95% C	1	IV. Rands	am. 95% CI		Study or Subgroup	Mean	50 T	dal Me	nan -	SD T	otal W	tight	IV. Random, 95% CI	IV. Ba	ndom, 95% CI	
1 Vitamin D+30r	ig/mi wit	h air limi	tation(FEV1%	(80%))							1.3.1 Adults											
BA52017		20.52		17.95	15.52	20	8.3N	1.17 [-9.49, 11.83]	1		-		AB8AS2017	19.12		24 17	95 1	5.52		6.3%	1.17 [-9.40, 11.83]		-	-
2017	7.5	8.25	32	-1.5	8.5	20	14.2%	9.00 [4.75, 13.25]	13				AN2017	7.5	8.25	32 -	1.5	8.5		4.2%	9.00 [4,75, 13.25]			_
h2014	13.7	9.31	64	52	7.5	66	15.2%	8.50 [5.50, 11.41]					Anshi2014	13.7		64	5.2	7.5	65 1	5.2%	8.50 [5.50, 11.41]			-
stotal (95% CI)			120			114	37.7%	8.30 [5.95, 10.64]			•		de Groot2015	-1.7				7.62		8.9%	1.90 [-7.96, 11.76]			-
arogeneity: Tau*				0=91	40); 1* =	0%							Martineau2015	-1.4		25	0 20			3,4%	-1.40 [-8.43, 3.63]		-	
at for overall effect	t Z = 6.9	(P < 0.0	(1000										Subtotal (95% CI)			67				0.1%	4.65 [0.02, 9.28]		-	
													Helerogeneity: Tauf I				(P=0.	006); #	* 72%					
2 Viamin D<30n													Test for overall effect	Z=1.97	(P=0.05)									
Greet2015		15.7	22		17,62	22	8.9%	1.90 [-7.96, 11.76]			-													
hey2016		5.037	- 6	4.5	6.07	8	12.7%	-8.00 [-13.83, -2.17]					1.3.2 Children											
r5reau(2015	-1.4	19.95	125	0	20.603	125	13.4%	-1.40 [-6.43, 3.63]					Kertey2018		5.037			0.07		2.7%	-8.00 [-13.83, -2.17]			
stocal (95% CI)		2.22	153	1000	10.10	155	35.1%	-3.18 [-8.60, 2.24]					Majak2009		4.49			2.00		5.5%	-0.70 [-3.16, 1.76]	12		
terogeneity: Tau*				50.+0	2.13; P	- 51%							Majak2011	4.6	12.16	24	4.4 1	2.05	24 1		0.20 [-8.65, 7.05]			
it for overall effect	t Z= 1.5	0=03	5)										Subtotal (95% CI)	1.1						9.9%	-2.60 [-7.26, 2.06]			
													Heterogeneity Tau*				a. = 0.0	73 P = 1	535					
3 Vitamin D>30r													Test for overall effect	Z=1.09	(P=0.27)									
jak2009 jak2011		4.49	18	1.4	2.86	18	15.5% 11.7%	-0.70 [-3.16, 1.76]					Total (95% CB			15			311 10		1.55 (-2.83, 5.93)		-	
ak2011 stotal (95%, CIS	4.6	12,16	24	4.4	12.05	24	27.2%	0.20 [-6.65, 7.05]			1		Hatsroponeity Tau*								****a [*£**** ****3]		-	
eroceneity; Tau*	- 0.00- 0			/R = 0			11.2%	a.au (47.91, 1.72)					Test for overall effect			. er = 7	(In = 0	00001);	P = 851	•		-20 -10	0 1	D
t for overall effect				(P=0.	01); !* =	0%							Test for subgroup diff				(B - 0		79.6%			Favours (cont	rol] Favours [e	xperimer
st for overall effect	2 = 0.5	(+=0.0	,										rescior socurous un	erences.	UR = 4.0	. 01 - 1	IP = 0.	031.1-	10.0 %					
al (95% CI)			315			311	100.0%	1.55 [-2.83, 5.93]		-														
erogeneity; Tau*	- 30 49 4			- 7 /0 -	0.00001			1.00 [-1.00, 0.00]			-													
									-20	-10														
	7 = 0.6								-20		0 10	20												
st for overall offect				t=2(P	< 0.0000	1) P=	94 1%		-20	Favours (control)														
st for overall offect	ferences:	Ch# = 3	3.84. di			01), P =	94.1%		-20	Favours (control)	Favours (experim	nental]	D				20	2012						
st for overall offect st for suborouo dif	ferences: Exp	Chi ^p = 3	3.84. di	c	Intro			Mean Difference		Favours (control) Mean D	Favours (experim	nental]	D		erimental		Cor			aar	Mean Difference		Difference	
at for overall offect at for suboroup dif	ferences: Exp	Chi ^p = 3	3.84. di	c	Intro			Mean Difference IV. Random, 95% C		Favours (control) Mean D	Favours (experim	nental]	Bludy or Bubgroup			tal Me			istal W	eight .	Mean Difference IV. Random, 85% Cl		Difference ndom, 95% Cl	
st for overall offect st for suborouo dif adv or Suboroup 1.1 <800 JUId	terences Exp Mean	ChP = 3 erment 8D	al al Total	C Mean	ontrol SD	Total	Weight	IV. Random, 95% C	a	Favours (control) Mean D	Favours (experim Merence am. 95% Cl	nental)	Bludy or Bubgroup 1.5.1 < 6 months	Mean	50 T		ean .	SD T			IV. Random, 95% CI			
st for overall effect at for suboroup dif atly or Subgroup .1 <800 Kild 2017	ferences Exp Mean 7.5	ChP = 3 eriment 8D 8.25	3.84. di al <u>Total</u> 32	Masn -1.5	entrol SD 8.5	Total 26	Weight	IV. Random, 95% C	a	Favours (control) Mean D	Favours (experim	nental)	Bludy or Bubgroup 1.5.1 < 6 months ABBAS2017	Mean 19,12	5D T	24 17	95 1	SD T	20	8.3%	IV. Random, 95% Cl			
at for overall effect at for subarous dif ady or Subarous 1 <800 JU/d 1017 ak2011	ferences Exp Mean 7.5	ChP = 3 erment 8D	3.84. dl al <u>Total</u> 32 24	Masn -1.5	ontrol SD	Total 28 24	Weight. 14.2% 11.7%	IV. Random. 95% C 8.00 (4.75, 13.25) 0.20 (4.65, 7.05)	a	Favours (control) Mean D	Favours (experim Merence am. 95% Cl	nental)	Bludy or Bubgroup 1.5.1 < 6 months ABBAS2017 AI2017	Mean 19,12 7.5	50 Tr 20.52 8.25	24 17	95 1 1.5	5.52 8.5	20 28 1	8.3%	N. Random, 95% Cl 1.17 [-9.49, 11.83] 9.00 [4.75, 13.25]			
st for overall effect at for suboroup dif sty or Suboroup dif 1, 4800 KUId 2017 (aK2011 bitotal (95% Ci)	ferences: Exp Mean 7.5 4.6	ChP = 3 enment 80 8.25 12.16	3.84. dl si <u>Total</u> 32 24 56	-1.5 4.4	8.5 12.05	Total 28 24 52	Weight	IV. Random, 95% C	a	Favours (control) Mean D	Favours (experim Merence am. 95% Cl	nental)	Bludy or Bubgroup 1.5.1 < 6 months ABBAS2017 AE2017 de Groc2015	Mean 19,12 7.5 -1.7	50 Tr 20.52 8.25 15.7	24 17 32 - 22 -	95 1 1.5 3.6 1	5.52 8.5 7.62	20 28 22	8.3% 4.2% 8.9%	IV. Random, 89% CI 1.17 [-9.49, 11.63] 9.00 [4.75, 13.25] 1.90 [-7.96, 11.76]			
st for overall effect at or suboroup diffect of a suboroup diffect suboroup diffect suboroup diffect at 2017 (at 2011 (at 2011) (at 2011	Exp Exp Mean 7.5 4.6 = 30.26; 1	ChP = 3 eriment 80 8.25 12.16 50F = 4.1	3.84. dt It Total 32 24 56 a, df =	-1.5 4.4	8.5 12.05	Total 28 24 52	Weight. 14.2% 11.7%	IV. Random. 95% C 8.00 (4.75, 13.25) 0.20 (4.65, 7.05)	a	Favours (control) Mean D	Favours (experim Merence am. 95% Cl	nental)	Bludy or Bubgroup 1.5.1 < 6 months ABBAS2017 AI2017 de GrooC015 Kertey2016	Mean 19,12 7.5 -1.7	50 Tr 20.52 8.25	24 17 32 - 22 -	95 1 1.5 3.6 1	5.52 8.5	20 28 22 8	8.3% 4.2% 8.9% 2.7%	N. Random, 95% Cl 1.17 (-9.49, 11.83) 9.00 (4.75, 13.25) 1.90 (-7.96, 11.78) -8.00 (-13.83, -2.17)			
tt for overall effect tt for suberoue dif dy or Suberoue 1 <800 KUd 5017 (#2011 stotal (95% Ci) aregenety: Tau ⁴	Exp Exp Mean 7.5 4.6 = 30.26; 1	ChP = 3 eriment 80 8.25 12.16 50F = 4.1	3.84. dt It Total 32 24 56 a, df =	-1.5 4.4	8.5 12.05	Total 28 24 52	Weight. 14.2% 11.7%	IV. Random. 95% C 8.00 (4.75, 13.25) 0.20 (4.65, 7.05)	a	Favours (control) Mean D	Favours (experim Merence am. 95% Cl	nental]	Bludy or Bubgroup 1.5.1 < 6 months ABBA52017 AI2017	Mean 19.12 7.5 -1.7 -3.5	50 Tr 20.52 6.25 15.7 5.037	24 17 32 - 22 - 6 84	95 1 1.5 3.6 1 4.5	80 T 5.52 8.5 7.62 6.07	20 28 22 8 78	8.3% 4.2% 8.9%	IV. Random, 89% CI 1.17 [-9.49, 11.63] 9.00 [4.75, 13.25] 1.90 [-7.96, 11.76]			
It for overall effect the suberous diffect the sube	Exp Exp Mean 7.5 4.6 = 30.26; 1	ChP = 3 eriment 80 8.25 12.16 50F = 4.1	3.84. dt It Total 32 24 56 a, df =	-1.5 4.4	8.5 12.05	Total 28 24 52	Weight. 14.2% 11.7%	IV. Random. 95% C 8.00 (4.75, 13.25) 0.20 (4.65, 7.05)	a	Favours (control) Mean D	Favours (experim Merence am. 95% Cl	nental]	Bludy or Bubgroup 1.5.1 < 6 months ABBAS2017 AI2017 de Grooc2015 Kertey2018 Subtotal (\$5% CI) Heterogeneity: Teu ⁴	Mean 19,12 7.5 -1.7 -3.5	<u>80 T</u> 20.52 8.25 15.7 5.037	24 17 32 - 22 - 6 84	95 1 1.5 3.6 1 4.5	8D T 5.52 8.5 7.62 6.07	20 28 22 8 78	8.3% 4.2% 8.9% 2.7%	N. Random, 95% Cl 1.17 (-9.49, 11.83) 9.00 (4.75, 13.25) 1.90 (-7.96, 11.78) -8.00 (-13.83, -2.17)			
t for overall offect t for suberoue dif dy or Suberoue 1 <800 KM 017 ax2011 ax2	Exp Exp Mean 7.5 4.6 = 30.26; 1 t Z = 1.19	6.25 12.16 507 = 4.1 (P = 0.2	3,84. dt at <u>Totai</u> 32 24 54 34, dt = (5)	C -1.5 4.4 1 (P = 1	8.5 12.05	Total 28 24 52 78%	Weight 14.2% 11.7% 25.8%	IV. Bandom, 95% C 8.00 (4.75, 13.25) 0.20 (-8.65, 7.05) 5.03 (-3.56, 13.61)	a	Favours (control) Mean D	Favours (experim Merence am. 95% Cl	nental]	Bludy or Bubgroup 1.5.1 < 6 months ABBA52017 AI2017	Mean 19,12 7.5 -1.7 -3.5	<u>80 T</u> 20.52 8.25 15.7 5.037	24 17 32 - 22 - 6 84	95 1 1.5 3.6 1 4.5	8D T 5.52 8.5 7.62 6.07	20 28 22 8 78	8.3% 4.2% 8.9% 2.7%	N. Random, 95% Cl 1.17 (-9.49, 11.83) 9.00 (4.75, 13.25) 1.90 (-7.96, 11.78) -8.00 (-13.83, -2.17)			
It for overall effect the suberous diffectuation of the suberous diffectuation (1 < 800 BUIs (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	ferences: Exp Mean 7.5 4.6 = 30.26; 1 t Z = 1.11 19.12	ChP = 3 eriment 8D 8.25 12.16 5hP = 4.1 5(P = 0.2 20.52	3.84. dt it <u>Total</u> 32 24 56 a, df = (5) 24	-1.5 -1.5 4.4 1 (P = 1 17.95	8.5 12.05 15.52	Total 26 24 52 78%	Weight 14.2% 11.7% 25.8% 6.3%	N. Random. 35% C 8.00 (4.75, 13.25) 0.20 (4.65, 7.05) 5.03 (-3.56, 13.61) 1.17 (-9.49, 11.83)	a	Favours (control) Mean D	Favours (experim Merence am. 95% Cl	nental]	Bludy of Bubgroup 1.5.1 < 6 months ABBAS2017 AI2017 de Grooc2015 Karlex2018 Subtotal (55% CI) Heterogeneity: Teu ¹⁴ Test for overall effect	Mean 19,12 7.5 -1.7 -3.5	<u>80 T</u> 20.52 8.25 15.7 5.037	24 17 32 - 22 - 6 84	95 1 1.5 3.6 1 4.5	8D T 5.52 8.5 7.62 6.07	20 28 22 8 78	8.3% 4.2% 8.9% 2.7%	N. Random, 95% Cl 1.17 (-9.49, 11.83) 9.00 (4.75, 13.25) 1.90 (-7.96, 11.78) -8.00 (-13.83, -2.17)			
It for overall effect the subsroue differences of the subsroue differences (1 <000 RUId (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	ferences: Exp Mean 7.5 4.6 = 30.26; 1 t Z = 1.11 19.12	6.25 12.16 507 = 4.1 (P = 0.2	3.84. dt it <u>Total</u> 32 24 50 32 55 24 0	-1.5 -1.5 4.4 1 (P = 1 17.95	8.5 12.05	Total 28 24 52 78% 20 6	Weight 14.2% 11.7% 25.8% 6.3% 12.7%	N. Random. 95% C 8.00 [4.75, 13.25] 0.20 [4.85, 7.05] 5.03 [-3.56, 13.61] 1.17 [-9.49, 11.83] 8.00 [-13.83, -2.17]	a	Favours (control) Mean D	Favours (experim Merence am. 95% Cl	nenta()	Bludy or Bubgroup 1.5.1 < 6 months ABBAS2017 ABBAS2017 de Groo2015 Kartes2018 Subtoal (55% CI) Heteroperaty: Tau ² Test for overall effect 1.5.2 6 months	Mean 19,12 7.5 -1.7 -3.5 74,89; C Z = 0.23	50 T 20.52 8.25 15.7 5.037 5.037 5.037	24 17 32 - 22 - 8 84 .dl=3	95 1 15 38 1 45	50 T 5.52 8.5 7.62 6.07 0001); 1	20 28 22 8 78 *= 66%	8.3% 4.2% 8.9% 2.7% 4.1%	IV. Random, 89% Cl 1.17 [-0.40, 11.63] 9.00 [4.75, 13.25] 1.90 [-7.96, 11.76] -8.00 [-13.83, -2.17] 1.08 [-6.20, 10.42]			
It for overall effect the subsroue difference of the subsroue difference (subsroue) and subsroue (subsroue) and subsroue (subs	ferences: Exp Mean 7.5 4.6 = 30.26; i t Z = 1.11 19,12 -3.5	ChP = 3 eniment 8D 8.25 12.16 507 = 4.1 5 (P = 0.2 5.037	3.84. dt it <u>Total</u> 32 24 56 4, dt = (5) 24 0 30	C -1.5 4.4 1 (P = 1 17.95 4.5	6.5 12.05 15.52 6.07	Total 28 24 52 73% 20 6 28	Weight 14.2% 11.7% 25.8% 6.3% 12.7%	N. Random. 35% C 8.00 (4.75, 13.25) 0.20 (4.65, 7.05) 5.03 (-3.56, 13.61) 1.17 (-9.49, 11.83)	a	Favours (control) Mean D	Favours (experim Merence am. 95% Cl	nental]	Bludy or Bubgroup 1.5.1 < 6 months ABBAS2017 AI2017 de Groo2015 Kerles2016 Subteal (55% CI) Heteropeneity: Tau ⁴ Test for overall effect 1.5.2 6 months Arab/2014	Mean 19,12 7.5 -1.7 -3.5 74,89; C Z = 0.23 13,7	8D Tr 20.52 8.25 15.7 5.037 m ² = 21.4 (P = 0.82) 9.31	24 17 32 - 22 - 6 M d(= 3	1.5 1.5 3.8 1 4.5 1(P < 0 5.2	50 T 5.52 8.5 7.62 6.07 0001); 1 7.5	20 28 22 8 78 66 1	8.3% 4.2% 8.9% 2.7% 4.1%	M. Random, 85% Cl 1.17 [-9.49, 11.03] 8.00 [4.75, 13.25] 1.30 [-7.96, 11.78] 8.00 [-7.86, 11.78] 1.08 [-8.26, 10.47] 8.50 [5.59, 11.41]			
It for overall effect that subsroup differences in 4800 RU(d) 114800 RU(d) 117800 RU(d) 117800 RU(d) 11800 RU(d) 1	Terences: Exp Mean 7.5 4.6 = 30.26; 1 t Z = 1.10 19,12 -3.5 = 22,83, 1	ChP = 3 eniment 80 8.25 12.16 5hP = 4.1 (P = 0.3 20.52 5.037 5hP = 2.1	3.84. dt 1 32 24 56 3, dt = 5) 24 0 30 9, dt =	C -1.5 4.4 1 (P = 1 17.95 4.5	6.5 12.05 15.52 6.07	Total 28 24 52 73% 20 6 28	Weight 14.2% 11.7% 25.8% 6.3% 12.7%	N. Random. 95% C 8.00 [4.75, 13.25] 0.20 [4.85, 7.05] 5.03 [-3.56, 13.81] 1.17 [-9.49, 11.83] 8.00 [-13.83, -2.17]	a	Favours (control) Mean D	Favours (experim Merence am. 95% Cl	nental]	Bludy or Bubgroup 1.5.1 < 6 months ABBAS2017 ABBAS2017 de Groo2015 Kartes2018 Subtoal (55% CI) Heteroperaty: Tau ² Test for overall effect 1.5.2 6 months	Mean 19,12 7.5 -1.7 -3.5 74,89; C Z = 0.23 13,7	8D Tr 20.52 8.25 15.7 5.037 m ² = 21.4 (P = 0.82) 9.31	24 17 32 - 22 - 6 M d(= 3	1.5 1.5 3.8 1 4.5 1(P < 0 5.2	50 T 5.52 8.5 7.62 6.07 0001); 1 7.5	20 28 1 22 8 1 78 4 60 1 24	8.3% 4.2% 8.9% 2.7% 4.1%	M. Random, 85% Cl 1.17 [-9.49, 11.63] 9.00 [4.75, 13.25] 1.30 [-7.96, 11.76] 8.00 [-13.81, -2.17] 1.06 [-8.20, 10.42] 8.50 [5.39, 11.41] 0.20 [-8.66, 7.05]			
ti for overall effect at for subsroup diffect and an abstrong diffect an abstrong	Terences: Exp Mean 7.5 4.6 = 30.26; 1 t Z = 1.10 19,12 -3.5 = 22,83, 1	ChP = 3 eniment 80 8.25 12.16 5hP = 4.1 (P = 0.3 20.52 5.037 5hP = 2.1	3.84. dt 1 32 24 56 3, dt = 5) 24 0 30 9, dt =	C -1.5 4.4 1 (P = 1 17.95 4.5	6.5 12.05 15.52 6.07	Total 28 24 52 73% 20 6 28	Weight 14.2% 11.7% 25.8% 6.3% 12.7%	N. Random. 95% C 8.00 [4.75, 13.25] 0.20 [4.85, 7.05] 5.03 [-3.56, 13.81] 1.17 [-9.49, 11.83] 8.00 [-13.83, -2.17]	a	Favours (control) Mean D	Favours (experim Merence am. 95% Cl	nental]	Thudy or Subgroup 1.5.1 4 6 menths ABBAS2017 AI2017 de Groec016 Subtotal (36% Cl) Heterogeneity: Tax ² - Test for overal effect 1.5.2 6 months Arah2014 Maga2011 Subtotal (36% Cl)	Mean 19,12 7.5 -1.7 -3.5 74,80, C Z = 0.23 13,7 4,8	<u>80 1</u> 20.52 8.25 15.7 5.037 24 ⁶ = 21.4 (P = 0.82) 9.31 12.16	24 17 32 - 22 - 6 84 64 24 88	52 4.4	50 T 5.52 8.5 7.62 6.07 0001); 1 7.5 2.05	20 28 1 22 8 1 78 4 1 66 1 24 1 90 3	8.3% 4.2% 8.9% 2.7% 4.1% 5.2%	M. Random, 85% Cl 1.17 [-9.49, 11.03] 8.00 [4.75, 13.25] 1.30 [-7.96, 11.78] 8.00 [-7.86, 11.78] 1.08 [-8.26, 10.47] 8.50 [5.59, 11.41]			
the overall effect at for subsroup diffect day or Subsroup diffect participation and the participation of the part	Terencess Exp Mean 7.5 4.6 = 30.26; i t Z = 1.19 19.12 -3.5 = 22.83; i t Z = 1.05	ChP = 3 eniment 80 8.25 12.16 5hP = 4.1 (P = 0.3 20.52 5.037 5hP = 2.1	3.84. dt 1 32 24 56 3, dt = 5) 24 0 30 9, dt =	C -1.5 4.4 1 (P = 1 17.95 4.5	6.5 12.05 15.52 6.07	Total 28 24 52 73% 20 6 28	Weight 14.2% 11.7% 25.8% 6.3% 12.7%	N. Random. 95% C 8.00 [4.75, 13.25] 0.20 [4.85, 7.05] 5.03 [-3.56, 13.81] 1.17 [-9.49, 11.83] 8.00 [-13.83, -2.17]	a	Favours (control) Mean D	Favours (experim Merence am. 95% Cl	nental]	Bludy or Bubgroup 1.5.1 4 6 menths ABBAS2017 AU2017 do Grosof015 Kartex2018 Subtoal (1955 CI) Heleropensity: Tau ²¹ Test for overall effect 1.5.2 6 months Arah2014 Majas2011 Subtoal (1965 CI) Heteropensity: Tau ²¹	Mean 19,12 7.5 -1.7 -3.5 74,89; C 2 = 0.23 13,7 4.6 :27,34; C	<u>\$0 1</u> , 20.52 8.25 16.7 5.037 29 ² = 21.4 (P = 0.82) 9.31 12.16 29 ² = 4.78	24 17 32 - 6 6 64 24 64 24 64	52 4.4	50 T 5.52 8.5 7.62 6.07 0001); 1 7.5 2.05	20 28 1 22 8 1 78 4 1 66 1 24 1 90 3	8.3% 4.2% 8.9% 2.7% 4.1% 5.2%	M. Random, 85% Cl 1.17 [-9.49, 11.63] 9.00 [4.75, 13.25] 1.30 [-7.96, 11.76] 8.00 [-13.81, -2.17] 1.06 [-8.20, 10.42] 8.50 [5.39, 11.41] 0.20 [-8.66, 7.05]			<u> </u>
the overall effect the subserve of de or Subserve of the subserve of states of the states of the sta	Exp Exp Mean 7.5 4.6 = 30.24; i t Z = 1.19 19.12 -3.5 = 22.83; i t Z = 1.05 yh-dose	ChP = 3 80 8.25 12.16 ChP = 0.1 20.52 5.037 ChP = 2.1 (P = 0.1	3.84. dt 1 32 24 56 3, dt = 5) 24 0 30 9, dt =	-1.5 4.4 1 (P = 1 17.95 4.5 1 (P = 1	entrol 5D 8.5 12.05 103): P 15.52 6.07 2.14): P	Total 28 24 52 78% 20 6 28 54%	Weight 14.2% 11.7% 25.8% 8.3% 12.7% 21.0%	M. Bandom, 1935 C 0.00 (4.75, 13.25) 0.20 (4.65, 7.06) 5.03 (-3.56, 13.81) 1.17 (-0.49, 11.83) 4.00 (-13.83, -2.17) -4.55 (-13.26, 4.16)	1	Favours (control) Mean D	Favours (experim Merence am. 95% Cl	nental]	Thudy or Subgroup 1.5.1 4 6 menths ABBAS2017 AI2017 de Groec016 Subtotal (36% Cl) Heterogeneity: Tax ² - Test for overal effect 1.5.2 6 months Arah2014 Maga2011 Subtotal (36% Cl)	Mean 19,12 7.5 -1.7 -3.5 74,89; C 2 = 0.23 13,7 4.6 :27,34; C	<u>\$0 1</u> , 20.52 8.25 16.7 5.037 29 ² = 21.4 (P = 0.82) 9.31 12.16 29 ² = 4.78	24 17 32 - 6 6 64 24 64 24 64	52 4.4	50 T 5.52 8.5 7.62 6.07 0001); 1 7.5 2.05	20 28 1 22 8 1 78 4 1 66 1 24 1 90 3	8.3% 4.2% 8.9% 2.7% 4.1% 5.2%	M. Random, 85% Cl 1.17 [-9.49, 11.63] 9.00 [4.75, 13.25] 1.30 [-7.96, 11.76] 8.00 [-13.81, -2.17] 1.06 [-8.20, 10.42] 8.50 [5.39, 11.41] 0.20 [-8.66, 7.05]			
et for overall effect it for suborous di dir or Suborous di suborous di suboro	Exp Mean 7.5 4.6 = 30.26; i t Z = 1.19 19.12 -3.5 = 22.83; i t Z = 1.0 yh-dose 13.7	ChP = 3 seriments 825 12.16 507 = 4.1 (P = 0.2 20.52 5.037 507 = 2.1 (P = 0.2 9.31	3.84. dl it <u>Total</u> 32 24 56 3, df = 5) 24 0 30 9, df = 1) 64	-1.5 4.4 1 (P = 1 17.95 4.5 1 (P = 0 5.2	entrol 5D 8.5 12.05 10.33 F 15.52 6.07 3.143 F 7.5	Total 28 52 78% 20 6 23 54% 66	Weight 14.2% 11.7% 25.8% 8.3% 12.7% 21.0%	M. Bandom. 39% C 0.00 (4.75, 13.25) 0.20 (-4.65, 7.05) 5.03 (-3.56, 13.81) 1.37 (-0.49, 11.53) 4.00 (-13.83, -2.17) -4.55 (-13.26, 4.16) 8.50 (5.59, 11.41)		Favours (control) Mean D	Favours (experim Merence am. 95% Cl	nerta]	Bludy or Bubgroup 1.5.1 4 6 menths ABBAS2017 AU2017 do Grosof015 Kartex2018 Subtoal (1955 CI) Heleropensity: Tau ²¹ Test for overall effect 1.5.2 6 months Arah2014 Majas2011 Subtoal (1965 CI) Heteropensity: Tau ²¹	Mean 19,12 7.5 -1.7 -3.5 74,89; C 2 = 0.23 13,7 4.6 :27,34; C	<u>\$0 1</u> , 20.52 8.25 16.7 5.037 29 ² = 21.4 (P = 0.82) 9.31 12.16 29 ² = 4.78	24 17 32 - 6 6 64 24 64 24 64	52 4.4	50 T 5.52 8.5 7.62 6.07 0001); 1 7.5 2.05	20 28 1 22 8 1 78 4 1 66 1 24 1 90 3	8.3% 4.2% 8.9% 2.7% 4.1% 5.2%	M. Random, 85% Cl 1.17 [-9.49, 11.63] 9.00 [4.75, 13.25] 1.30 [-7.96, 11.76] 8.00 [-13.81, -2.17] 1.06 [-8.20, 10.42] 8.50 [5.39, 11.41] 0.20 [-8.66, 7.05]			
t for overall office it for subprouse 1 < subprou	Exp Mean 7.5 4.6 = 30.26; 1 t Z = 1.10 19,12 -3.5 = 22,83; 1 t Z = 1.65 yh-dose 13,7 -1,7	ChP = 3 eriment 80 825 12.16 50P = 4.1 (P = 0.2 5.037 50P = 2.1 (P = 0.2 5.037 50P = 2.1 (P = 0.2 5.037 50P = 3 50P = 3 50	3.84. dl il Total 32 24 56 a, df = (5) 24 6 30 9, df = (1) 64 22	-1.5 4.4 1 (P = 1 17.95 4.5 1 (P = 1 5.2 -3.6	ontrol 80 8.5 12.05 103): P1 15.52 6.07 2.14]; P1 7.5 17.62	Total 28 28 52 73% 20 6 23 54% 66 22	Weight 14.2% 11.7% 25.8% 8.3% 12.7% 21.0%	M. Bandom, 39% C 6 00 (4.75, 13.25) 0.20 (4.65, 7.65) 5.03 (-3.56, 13.81) 1.17 (-0.45, 11.83) 4.00 (-13.82, -2.17) -4.55 (-13.26, 4.16) 6.50 (5.50, 11.41) 1.50 (-7.96, 11.75)		Favours (control) Mean D	Favours (experim Merence am. 95% Cl	nental]	Bludy of Bubgeoup 1.5.1 < 6 menths ABBA32017 A02017 A02017 A02017 A02017 East Conversit effect Subteau (25% CT) Netwogravely: Tau ² - Test for oversit effect Analy2014 Majaco11 Subteau (20% CT) Hetmogravely: Tau ² - Test for oversit effect 1.5.3 Ho months	Mean 19,12 7,5 -1,7 -3,5 -74,86; C Z = 0,23 13,7 4,8 -27,34; C Z = 1,21	<u>80 T</u> 20.52 8.25 15.7 5.037 26 ² = 21.44 (P = 0.82) 9.31 12.16 26 ² = 4.78 (P = 0.22)	24 17 32 - 6 84 64 24 67 = 1 (52 64 795 715 715 715 715 715 715 715 715 715 71	80 T 5.52 8.5 7.62 6.07 0001); 1 7.5 (2.05 0); P =	20 28 1 22 8 1 78 60 1 24 1 24 1 24 1 24 1 27 50 79%	8.3% 4.2% 8.9% 2.7% 4.1% 5.2% 1.7%	N. Random, BYS CT. 1.17 [449, 11.83] 8.00 [475, 13.26] 8.00 [-38.3, -2.17] 1.00 [-38.3, -2.17] 1.00 [-4.65, 10.47] 8.50 [5.59, 11.41] 0.20 [4.65, 7.05] 4.50 [-5.69, 13.69]			
t for overall office t for autorous off for autorous off for autorous off for autorous office for overall effect (b) roverall eff	Exp Maan 7.5 4.6 = 30.26; i E Z = 1.10 19.12 -3.5 = 22.83; i E Z = 1.05 (ph-dose 13.7 -1.7 0.7 0.7	ChP = 3 eriments 80 8.25 12.16 50P = 4.1 (P = 0.2 20.52 5.037 50P = 2.1 10P = 0.3 9.31 15.7 4.49	3384. dt <u>1 Total</u> <u>32</u> 24 56 30 30 9. dt = 11 64 22 18	-1.5 -1.5 -1.5 -1.5 -1.5 1 (P = 1) -3.6 1.4	entrol <u>50</u> 8.5 12.05 103) F 15.52 6.07 14) F 7.5 17.62 2.66	Total 28 24 52 73% 20 6 28 54% 54% 54% 54%	Weight 14.2% 11.7% 25.3% 6.3% 12.7% 21.0% 15.2% 8.9% 15.5%	M. Bandom, 35% G 8:00 (4.75, 13.25) 0:20 (-8.65, 7.66) 3:03 (-3.56, 13.81) 1:17 (-0.49, 11.83) 8:00 (-13.83, -2.17) 4:55 (-13.28, 4.16) 8:50 (5.59, 11.41) 1:00 (-7.96, 11.78) -0.79 (-3.18, 17.78)		Favours (control) Mean D	Favours (experim Merence am. 95% Cl	nerta]	Bludy of Subgroup 1.5.1 < 6 months ABBAS2017 AI2017 AI2017 Subbas1(2016 Subbas1(2016 Subbas1(2016 Subbas1(2016 Subbas1(2016) Subbas	Maan 19,12 75 -1,7 -3,5 -74,80, C Z = 0,23 13,7 4,8 -27,24; C Z = 1,21 0,7	<u>50 T</u> 20.52 8.25 16.7 5.037 20 ² = 21.4 (P = 0.82) 9.31 12.16 29 ² = 4.78, (P = 0.23) 4.49	24 17 32 - 6 84 64 24 67 = 1 (15 15 38 15 45 45 52 44 10 P=0.0	80 T 5.52 8.5 7.62 6.07 0001); 1 7.5 2.05 0); P = 2.86	20 28 1 22 8 1 78 4 * = 86% 60 1 24 1 24 1 1 24 1 1 1 1 1 1 1 1 1 1 1 1 1	8.3% 4.2% 8.9% 2.7% 4.1% 5.2% 5.2%	N. Random, 85% CI. 1.17 (-6.46, 11.83) 5.00 (-7.5, 13.56) 1.00 (-7.86, 1.1.76) 4.00 (-7.88, -2.17) 1.06 (-6.28, 1.1.61) 4.00 (-5.39, 11.41) 0.20 (-6.65, 7.05) 4.99 (-5.46, 1.76) 4.07 (-5.16, 1.78)			
at for overall officed aft for substrough off aft or substrough officed (1.4806 RUM 2017) (ar42011) (ar4206 RUM 2017) (ar42011) (ar4206 RUM 2017) (ar420111) (ar420111) (ar420111) (ar420111) (ar420111) (ar420111) (ar420111) (ar420111) (ar420111) (ar420111) (ar420111)	Exp Maan 7.5 4.6 = 30.26; i E Z = 1.10 19.12 -3.5 = 22.83; i E Z = 1.05 (ph-dose 13.7 -1.7 0.7 0.7	ChP = 3 eriment 80 825 12.16 50P = 4.1 (P = 0.2 5.037 50P = 2.1 (P = 0.2 5.037 50P = 2.1 (P = 0.2 5.037 50P = 3 50P = 3 50	3.84. dl il Total 32 24 56 a, df = (5) 24 6 30 9, df = (1) 64 22	-1.5 -1.5 -1.5 -1.5 -1.5 1 (P = 1) -3.6 1.4	ontrol 80 8.5 12.05 103): P1 15.52 6.07 2.14]; P1 7.5 17.62	Total 28 28 52 73% 20 6 23 54% 66 22	Weight 14.2% 11.7% 25.3% 5.3% 12.7% 21.0% 15.2% 8.9% 15.5% 13.4%	M. Bandem, 39% C 6 00 (4.75, 13.25) 0.20 (4.65, 7.65) 5.03 (-3.56, 13.81) 1.17 (-9.48, 11.83) 1.17 (-9.48, 11.83) 4.00 (-13.8, -2.17) -4.55 (-13.26, 4.16) 6.50 (5.50, 11.41) 1.50 (-7.96, 11.78) -0.70 (-3.18, 1.78) -0.70 (-3.18, 1.78)		Favours (control) Mean D	Favours (experim Merence am. 95% Cl	nontal]	Bludy of Bubgeoup 1.5.1 < 6 menths ABBA32017 A02017 A02017 A02017 A02017 East Conversit effect Subteau (25% CT) Netwogravely: Tau ² - Test for oversit effect Analy2014 Majaco11 Subteau (20% CT) Hetmogravely: Tau ² - Test for oversit effect 1.5.3 Ho months	Maan 19,12 75 -1,7 -3,5 -74,80, C Z = 0,23 13,7 4,8 -27,24; C Z = 1,21 0,7	<u>50 T</u> 20.52 8.25 15.7 5.037 pr = 21.4 (P = 0.82) 9.31 12.16 pr = 4.78 (P = 0.22) 4.49 19.95	24 17 32 - 6 54 54 54 64 24 67 = 1 (18	52 64 795 715 715 715 715 715 715 715 715 715 71	80 T 5.52 8.5 7.62 6.07 00011; 1 7.5 2.05 03; P = 2.56 0.503	20 28 1 22 8 1 78 4 * 66% 60 1 24 1 80 1 24 1 1 1 1 1 1 1 1 1 1 1 1 1	8.3% 4.2% 8.9% 2.7% 4.1% 5.2% 5.2%	N. Random, BYS CT. 1.17 [449, 11.83] 8.00 [475, 13.26] 8.00 [-38.3, -2.17] 1.00 [-38.3, -2.17] 1.00 [-4.65, 10.47] 8.50 [5.59, 11.41] 0.20 [4.65, 7.05] 4.50 [-5.69, 13.69]			
It for overall office (it for substrough office) office of the substrough office (it office) (it offic	Exp Maan 7.5 4.6 = 30.26; i t Z = 1.11 19.12 -3.5 = 22.83; i t Z = 1.2 yh-dose yh-dose 13.7 -1.7 0.7 -1.4	ChP = 3 80 825 12.15 50 ² = 4.1 (P = 0.2 20.52 5.037 50 ² = 2.1 (P = 0.3 15.7 4.49 19.95	3,24, dt I <u>Total</u> 32 24 56 30 3, dt = 24 6 30 9, dt = 11) 64 22 18 125 22 125 24 24 55 55 55 55 55 55 55 55 55 5	6 Maso -1.5 4.4 1 (P = 1 17.95 1 (P = 1) 52 -3.6 1.4 0	entrol 80 8.5 12.06 103) # 1 15.52 6.07 2.14] # 1 7.5 17.62 2.66 20.603	Total 28 24 52 73% 20 0 23 25 20 0 23 25 25 125 125 125 125	Weight 14.2% 11.7% 25.3% 5.3% 12.7% 21.0% 15.2% 5.5% 15.5% 13.4%	M. Bandom, 35% G 8:00 (4.75, 13.25) 0:20 (-8.65, 7.66) 3:03 (-3.56, 13.81) 1:17 (-0.49, 11.83) 8:00 (-13.83, -2.17) 4:55 (-13.28, 4.16) 8:50 (5.59, 11.41) 1:00 (-7.96, 11.78) -0.79 (-3.18, 17.78)		Favours (control) Mean D	Favours (experim Merence am. 95% Cl	nortal]	Bludge of Subgroup 1.5.1 < 6 menths ABBAS2017 AI2017 AI2017 Subteat (PSK CI) Helengeneity: Tar/- Test for overall effect 1.5.2 6 months Arsh2014 Mapa2011 Subteat (PSK CI) Subteat (PSK CI) Subteat (PSK CI) Subteat (PSK CI) Subteat (PSK CI) Subteat (PSK CI) Subteat (PSK CI)	Mean 19,12 7,5 -1,7 -3,5 -74,86; C Z = 0,23 13,7 4,6 -27,34; C Z = 1,21 0,7 -1,4	<u>\$0 T</u> 20.52 8.25 15.7 5.037 24 ⁹ = 21.4 (P = 0.82) 9.31 12.16 24.49 19.95	24 17 32 - 6 54 54 54 54 54 54 54 54 54 54 54 54 54	1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5	<u>80 T</u> 5.52 8.5 6.07 0001); 1 7.5 2.05 0); P = 2.56 3.603	20 28 1 22 8 1 7 6 6 1 24 1 1 1 1 1 1 1 1 1 1 1 1 1	8.3% 4.2% 8.9% 2.7% 4.1% 5.2% 5.5% 3.4%	N. Random, 855; C1 1.37 (444, 1153) 300 (475, 1533) 300 (475, 1533) 300 (475, 1533) 300 (475, 1533) 300 (4354, 1532) 300 (4354, 1542) 300 (4354, 1542) 430 (536, 1141) 0.30 (465, 705) 439 (436, 156) -4.70 (53.10, 176)			
I to overall office for subproup office subproup office subproup of subproup subproup of subproup subproup of subproup of subproup of subproup subproup of subproup of subproup of subproup subproup of subproup of subproup of subproup of subproup subproup of subproup of subproup of subproup of subproup subproup of subproup of subp	Exp Exp Maan 7.5 4.6 = 30.26; i t Z = 1.10 19.12 -3.5 = 22.83; i t Z = 1.6 yh-dose 13.7 -1.7 0.7 -1.4 = 28.21; i	ChP = 3 8D 825 12.16 5D = 4.1 (P = 0.2 5.037 5D = 2.1 (P = 0.3 5D = 2.1 10.7 4.49 19.95 5D = 25 5D = 25 5	3,84, dt Total 32 24 55 24 6 30 9, dt = 10 55 64 22 18 125 52 14, dt	6 Maso -1.5 4.4 1 (P = 1 17.95 1 (P = 1) 52 -3.6 1.4 0	entrol 80 8.5 12.06 103) # 1 15.52 6.07 2.14] # 1 7.5 17.62 2.66 20.603	Total 28 24 52 73% 20 0 23 25 20 0 23 25 25 125 125 125 125	Weight 14.2% 11.7% 25.3% 5.3% 12.7% 21.0% 15.2% 5.5% 15.5% 13.4%	M. Bandem, 39% C 6 00 (4.75, 13.25) 0.20 (4.65, 7.65) 5.03 (-3.56, 13.81) 1.17 (-9.48, 11.83) 1.17 (-9.48, 11.83) 4.00 (-13.8, -2.17) -4.55 (-13.26, 4.16) 6.50 (5.50, 11.41) 1.50 (-7.96, 11.78) -0.70 (-3.18, 1.78) -0.70 (-3.18, 1.78)		Favours (control) Mean D	Favours (experim Merence am. 95% Cl	nortal	Tudy or Subscool 1.5.1 < 6 menths ABBA32017 A22017 A22017 A22017 A22017 A22017 A22017 Bubtes(1555 Subtes(1555 C) Hoteropanely: Tar-1 Test for overall effect Assistant (c55 C) Hoteropanely: Tar-1 Test for overall effect 1.5.2 × 6 months Magin2001 Hoteropanely: Tar-1 Test for overall effect 1.5.3 × 6 months Magin2000 Matrimaz2015	Mean 19,12 7,5 -1,7 -3,5 -74,80, C Z = 0,23 13,7 4,6 27,24, C Z = 1,21 0,7 -1,4 -0,00; Ch	<u>50 T</u> 20.52 5.25 15.7 5.037 20 ⁴ = 21.4 (P = 0.82) 9.31 12.16 20 ⁴ = 4.78 (P = 0.23) 4.49 19.95	24 17 32 - 84 64 24 85 64 26 88 87 18 18 25 45 45 45	1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5	<u>80 T</u> 5.52 8.5 6.07 0001); 1 7.5 2.05 0); P = 2.56 3.603	20 28 1 22 8 1 7 6 6 1 24 1 1 1 1 1 1 1 1 1 1 1 1 1	8.3% 4.2% 8.9% 2.7% 4.1% 5.2% 5.5% 3.4%	N. Random, 855; C1 1.37 (444, 1153) 300 (475, 1533) 300 (475, 1533) 300 (475, 1533) 300 (475, 1533) 300 (4354, 1532) 300 (4354, 1542) 300 (4354, 1542) 430 (536, 1141) 0.30 (465, 705) 439 (436, 156) -4.70 (53.10, 176)			
I to overall office I to reactions office in the reaction office office reactions of the office reaction of the interaction of the interacti	Exp Exp Maan 7.5 4.6 = 30.26; i t Z = 1.10 19.12 -3.5 = 22.83; i t Z = 1.6 yh-dose 13.7 -1.7 0.7 -1.4 = 28.21; i	ChP = 3 8D 825 12.16 5D = 4.1 (P = 0.2 5.037 5D = 2.1 (P = 0.3 5D = 2.1 10.7 4.49 19.95 5D = 25 5D = 25 5	3,84, dt 1 32 24 55 30 9, dt = 125 228 125 229 14, dt 6)	6 Maso -1.5 4.4 1 (P = 1 17.95 1 (P = 1) 52 -3.6 1.4 0	entrol 80 8.5 12.06 103) # 1 15.52 6.07 2.14] # 1 7.5 17.62 2.66 20.603	Total 28 24 52 20 6 22 20 6 22 20 6 22 20 6 22 20 6 22 20 6 22 20 6 22 20 6 22 20 6 22 20 6 22 24 24 52 24 24 24 24 24 24 24 24 24 24 24 24 24	Weight 14.2% 11.7% 25.8% 6.3% 12.7% 21.0% 15.2% 8.9% 15.5% 13.5% 13.4% 15.5%	M. Bandom, 35% C 8:00 (4:75, 13.25) 0:20 (4:86, 13.25) 1:17 (-0.40, 11.43) 4:00 (-13.83, -2.17) 4:59 (-13.26, 4:16) 8:50 (5.59, 11.41) 1:00 (-5.90, 11.41) 1:00 (-5.90, 11.42) 2:01 (3:46, 13.26) 2:21 (3:46, 5:01)		Favours (control) Mean D	Favours (experim Merence am. 95% Cl	nortal	Study or Subscool 1.5.1 < 6 months ABBA32017 ABBA32017 ABBA32017 ad Groud2015 Kuths2018 Subteal (25% CI) Helenogenety: Tau ² Tast for overall effect Anh2014 Magha2011 Subscotts Anh2014 Magha2015 Machenau2015 M	Mean 19,12 7,5 -1,7 -3,5 -74,80, C Z = 0,23 13,7 4,6 27,24, C Z = 1,21 0,7 -1,4 -0,00; Ch	<u>\$0 1)</u> 20.52 8.25 15.7 5.037 35 ² = 21.4 (P = 0.82) 9.31 12.16 35 ² = 4.78, (P = 0.22) 4.49 19.95 (P = 0.46) (P = 0.46)	24 17 32 - 84 64 24 85 64 26 88 87 18 18 25 45 45 45	1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5	8D T 15.52 8.5 7.62 6.07 0001); 1 7.5 (2.06 13); P = 2.56 1603 (; P = 0)	20 28 178 178 178 178 178 178 178 17	8.3% 4.2% 8.9% 5.2% 5.2% 5.2% 5.2% 5.2% 5.2%	77. Random. 875. C1 1.77 444, 1153 150 4.75, 153 150 4.75, 153 150 4.76, 153 150 5.48, 11.81 150 5.38, 11.41 0.20 6.85, 7.03 4.98 4.86, 153 4.98 4.86, 153 4.94 4.64, 233 4.94 3.64, 157			
It for overall office of the relations office of the relations of the subserved of the relation of the relation of the subserved of the relation of the relation of the subserved of the subserve	Exp Maan 7.5 4.6 = 30.26.1 t Z = 1.11 19.12 -3.5 = 22.83.1 t Z = 1.61 gh-dose 13.7 -1.7 -1.4 = 28.21,1 t Z = 0.74	ChP = 3 eriments 825 507 = 41 (P = 02 20.52 5037 507 = 21 (P = 02 9.31 19.75 4.49 19.95 507 = 25 19.75 19.	3,244, dt at <u>10</u> <u>24</u> 56 24 50 24 50 24 50 24 50 24 50 24 50 30 9, dt = 125 125 125 125 125 125 125 125	C Maan -15 44 1 (P = 1 17.95 4.5 1 (P = 1) 52 -3.6 1.4 0 = 3 (P <	85 50 52.05 55.52 6.07 55.52 6.07 5.54 7.5 7.5 7.5 7.62 2.66 20.503 0.0001)	Total 28 52 73% 20 6 23% 54% 56 22 18 54% 521 19 77% 20 8 23% 54% 52 18 5231 19 78% 52 54% 52 52 52 52 52 52 52 52 52 52 52 52 52	Weight 14.2% 11.7% 25.3% 8.3% 12.7% 21.0% 15.2% 8.5% 15.5% 15.4% 8.3% 15.5% 15.4% 8.3% 15.9% 15.4% 15.4% 15.4% 15.4% 15.4% 15.5% 15.4% 15.4% 15.5% 15.5% 15.4% 15.5%	M. Bandem, 39% C 6 00 (4.75, 13.25) 0.20 (4.65, 7.65) 5.03 (-3.56, 13.81) 1.17 (-9.48, 11.83) 1.17 (-9.48, 11.83) 4.00 (-13.8, -2.17) -4.55 (-13.26, 4.16) 6.50 (5.50, 11.41) 1.50 (-7.96, 11.78) -0.70 (-3.18, 1.78) -0.70 (-3.18, 1.78)		Favours (control) Mean D JV. Rando	Favours (upperformed)	nortal	Study or Subscoop 1.5.1 < 6 months ABBA2017 ABBA2017 ABC017 do GroudOlf5 KintroudOlf5 Subscol (25% CI) Hoterogenety: Tau ³ Test for overall effect 1.5.2 6 months Abstoch (25% CI) Hoterogenety: Tau ³ Test for overall effect 1.5.3 - 6 months Abstoch (25% CI) Hoterogenety: Tau ³ Test for overall effect Test for overall effect	Mean 19,12 7,5 -1,7 -3,5 -74,80, C Z = 0,23 13,7 4,68 -27,24; C Z = 1,21 0,7 -1,4 -0,00; Ch Z = 0,74	50 T) 20.52 6.25 15.7 5.037 № = 21.4 (P = 0.82 9.31 12.16 № = 4.78, (P = 0.22) 4.49 19.95 № = 0.05, (P = 0.46)	24 17 32 - 22 - 64 64 64 64 64 18 18 125 45 10 115	195 1 15 1 15 1 16 P<0 52 1 64 1 P=0.0 14 0 20	80 T 5.52 8.5 7.62 6.07 00061); i 7.5 2.06 10; i ⁺ = 0 2.86 3603	20 23 1 22 3 78 4 **= 66% 60 1 **= 66% 60 1 **= 66% 13 1 125 1 143 1 143 1 144 3 311 1 K	8.3% 4.2% 8.9% 2.7% 5.2% 5.2% 5.2% 5.2% 5.2% 5.0%	N. Random, 855; C1 1.37 (444, 1153) 300 (475, 1533) 300 (475, 1533) 300 (475, 1533) 300 (475, 1533) 300 (4354, 1532) 300 (4354, 1542) 300 (4354, 1542) 430 (536, 1141) 0.30 (465, 705) 439 (436, 156) -4.70 (53.10, 176)			
st for overall effect st for suberoue dif edge or Suberoue	Exp Mean 7.5 4.6 = 30.2%; r 19.12 = 22.83; (t Z = 1.11 19.12 - 3.5 = 22.83; (t) Z = 1.11 19.12 - 3.5 = 22.83; (t) Z = 1.11 19.12 - 1.4 = 28.21; (t) = 28.22; (t) = 20.24; (t) = 2	ChP = 3 entiments 82 52 12.16 52 12.16 52 12.16 52 12.16 52 12.16 52 12.16 52 12.16 52 52 12.16 52 52 12.16 52 52 52 52 52 52 52 52 52 52	3.64. dt 1 1 1 1 24 50 24 50 3.6 50 3.6 50 3.6 50 3.7 50 3.7 50 3.7 50 3.7 50 3.7 50 3.7 50 3.7 50 3.7 50 3.7 50 50 50 50 50 50 50 50 50 50	C Maan -15 44 1 (P = 1 17.95 4.5 1 (P = 1) 52 -3.6 1.4 0 = 3 (P <	85 50 52.05 55.52 6.07 55.52 6.07 5.54 7.5 7.5 7.5 7.62 2.66 20.503 0.0001)	Total 28 52 73% 20 6 23% 54% 56 22 18 54% 521 19 77% 20 8 23% 54% 52 18 5231 19 78% 52 54% 52 52 52 52 52 52 52 52 52 52 52 52 52	Weight 14.2% 11.7% 25.3% 8.3% 12.7% 21.0% 15.2% 8.5% 15.5% 15.4% 8.3% 15.5% 15.4% 8.3% 15.9% 15.4% 15.4% 15.4% 15.4% 15.4% 15.5% 15.4% 15.4% 15.5% 15.5% 15.4% 15.5%	M. Bandom, 35% C 8:00 (4:75, 13.25) 0:20 (4:86, 13.25) 1:17 (-0.40, 11.43) 4:00 (-13.83, -2.17) 4:59 (-13.26, 4:16) 8:50 (5.59, 11.41) 1:00 (-5.90, 11.41) 1:00 (-5.90, 11.42) 2:01 (3:46, 13.26) 2:21 (3:46, 5:01)		Favours (control) Mean D JN, Randi	Favours (experim Merence am. 95% Cl	100	Study or Subscool 1.5.1 < 6 months ABBA32017 ABBA32017 ABBA32017 ad Groud2015 Kuths2018 Subteal (25% CI) Helenogenety: Tau ² Tast for overall effect Anh2014 Magha2011 Subscotts Anh2014 Magha2015 Machena2015 Ma	Mean 19,12 7,5 -1,7 -3,5 74,86, C Z = 0,23 13,7 4,6 27,24, C Z = 1,21 0,7 -1,4 -0,00; Ch Z = 0,74	50 T/ 20.52 6.25 16.7 5.037 5.037 9.31 12.16 № = 4.78, (P = 0.32) 4.49 19.95 № = 0.06, ((P = 0.46) (P = 0.42) (P = 0.32) 19.95 19.55 19.55 19.55 19.55 19.55 19.55 19.55 19.55 19.55 19.	24 17 32 - 22 - 54 54 54 54 54 54 54 54 54 54	195 1 15 1 15 1 16 P<0 52 1 64 1 P=0.0 14 0 20	80 T 5.52 8.5 7.62 6.07 00061); i 7.5 2.06 10; i ⁺ = 0 2.86 3603	20 23 1 22 3 78 4 **= 66% 60 1 **= 66% 60 1 **= 66% 13 1 125 1 143 1 143 1 144 3 311 1 K	8.3% 4.2% 8.9% 2.7% 5.2% 5.2% 5.2% 5.2% 5.2% 5.0%	77. Random. 875. C1 1.77 444, 1153 150 4.75, 153 150 4.75, 153 150 4.76, 153 150 5.48, 11.81 8.50 15.39, 11.41 0.20 4.85, 153 4.85 3.86, 153 4.85 3.86, 157 4.84 3.64, 157 4.84 3.64, 157	- M.B		

Figure 4 Pooled mean difference for the subgroup analyses of FEV_1 % (Panel A: subgroup analysis by baseline status of FEV_1 % and vitamin D; Panel B: subgroup analysis by different ages; Panel C: subgroup analysis by doses of vitamin D; Panel D: subgroup analysis by durations of vitamin D).

3.4.2. Asthma exacerbation

Seven studies [15-17,27,30-32] provided data on asthma exacerbation. Except for one study [31], others included patients with vitamin D insufficiency. Pooled evidence indicated that vitamin D supplementation was associated with a reduction in the rate of exacerbation compared with placebo ((RR:0.73 95%Cl (0.58, 0.92), with low heterogeneity (P = 0.39, $I^2 = 5\%$)) (Fig. 4A).

Evaluations of the influence of prespecified subgroup analyses on exacerbation were conducted. Vitamin D supplementation was associated with a lower rate of asthma exacerbation among those with vitamin D insufficiency ((RR:0.76 95%Cl (0.61, 0.95), with no heterogeneity (P = 0.52, $I^2 = 0\%$)). However, there was only one study in the subgroup of vitamin D sufficiency, and showed a consistent effect on exacerbation. With respect to different ages, we obtained a significant reduction in the rate of exacerbation in adults ((RR:0.75 95%Cl (0.59, 0.95), with no heterogeneity (P = 0.41, $I^2 = 0\%$)), but no such protective effect in children. Besides, it may be associated with a lower rate of exacerbation in the subgroup of less than six months of vitamin D treatment, which only contained one trial (RR: 0.43 95%Cl (0.22, 0.82)). Nevertheless, there was no significant association of other treatment durations and different doses of vitamin D with asthma exacerbation.

	Experim	ental	Contr	ol		Risk Ratio	Risk	Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H. Rand	om, 95% Cl	
Arshi2014	4	64	5	66	3.2%	0.82 [0.23, 2.93]		<u> </u>	
Castro2014	28	201	37	207	23.2%	0.78 [0.50, 1.22]		-	
Jensen2016	7	11	8	11	14.8%	0.88 [0.49, 1.55]		-	
Majak2011	4	24	11	24	5.1%	0.36 [0.13, 0.98]			
Martineau2015	42	125	51	125	41.3%	0.82 [0.60, 1.14]	-=	ł	
Musharraf 2017	9	40	21	40	11.8%	0.43 [0.22, 0.82]			
Rubén2017	1	53	0	53	0.5%	3.00 [0.12, 72.02]			
Total (95% CI)		518		526	100.0%	0.73 [0.58, 0.92]	♦		
Total events	95		133						
Heterogeneity: Tau ^a =	0.01; Chi*	= 6.31, 0	df = 6 (P =	= 0.39);	l² = 5%				404
Test for overall effect:	Z = 2.67 (P	= 0.007	ກົ				0.01 0.1 Favours [experimental]	I 10 Favours [control]	100

Figure 5 Pooled relative risk for asthma exacerbation with 95% confidence intervals of eligible studies comparing vitamin D versus

1	nl	a	ce	h	0	

¥	Experiment	at i	Control			Risk Retio	Risk Ratio	В	Experim	ental	Cont	rol		Risk Ratio	Risk Rati	•
	Events T				Weight	M-H. Random, 95% Ci	M-H. Random, \$5% Cl	Study or Subgroup 2.3.1 Adults	Eventa	Total	Events	Total	Weight	M-H. Random, 95% C	M-H. Random.	95% CI
2.1 Vitamin U<30ngm rshi2014		64	5	66	3.2%	0.6210.23, 2.931		Arshi2014		64	6	66	3.2%	0.82 (0.23, 2.93)		-
astro2014	28	201		207	23.2%	0.78 (0.50, 1.22)		Castro2014	28	201	37			0.7810.50. 1.22		
nsen2016	7	11	8	11	14.8%	0.8810.49, 1.55										
rtineau2015		125		125	41.3%	0.82 (0.60, 1.14)		Martineou/2015	42	125	51			0.82 [0.60, 1.14]		
sharraf 2017	- 0	40	21	40	11.8%	0.43 [0.22, 0.82]		Musharraf 2017	9	40	21			0.43 [0.22, 0.82]		
bin2017		53	0	53	0.5%	3 00 10 12, 72 021		Ruben2017	1	483	0			3.00 [0.12, 72.02]		
ibtotal (95% CI)	- ¹⁰ 3	494		502	94.9%	0.78 [0.61, 0.95]	•	Subtotal (\$5% CI)	1231	483	100	491	00.1%	0.75 [0.59, 0.95]		
kai eventa	91		122			and family and		Total events	84		114		107.02			
terogeneity: Tau* = 0) st for overail effect: Z	00; Chi* + 4			9.52k	*= 0%			Hetorogenoity: Tau ^a = Test for overall effect				= 0.41)	; i* = 0%			
2.2 Vitamin D>30ng/m								2.3.2 Children								
aiak2011	7 2	24	11	24	5.1%	0.36 (0.13, 0.98)		Jensen2016	7	11	8	11		0.88 (0.49, 1.55)		
abtotal (95% CI)		24		24	5.1%	0.36 [0.13, 0.98]	-	Majak2011	4	24	11			0.36 [0.13, 0.98]		
tal events		55	11	22				Subtotal (95% CI)		35		35	19.9%	0.61 [0.24, 1.58]	-	
terogeneity: Not apple	and a		0.120					Total events	11		19				· · · · ·	
at for overall effect: Z		0.05)						Heterogeneity: Tau* = Test for overall effect				- 0.09)	P = 65%			
tal (95% CI)		518		525	100.0%	0.73 [0.58, 0.92]	•									
tai events	95		133					Total (95% CI)		518		526	100.0%	0.73 [0.58, 0.92]	•	
Inregeneity: Tau* = 0)			6 (P=0	3.39%	1* = 5%		0.01 0.1 1 10 1	Total events	95		133					
st for overall effect: 2 st for suborous differe			= 1 <i>1</i> P	= 0.15	A. I* = 51.	156	Favours (experimental) Favours (control)	 Heterogeneity: Tau^a = Test for overall effect Test for subgroup diff 	Z=2.67 (9 = 0.00	2				0.01 0.1 1 [experimental] [cor	10 htrol)
8 .	Experiment	a - 1	Control			Risk Ratio	Risk Ratio	D	Experime	Intal	Contro	1.000		Risk Ratio	Risk Ratio	
					Weight	M-H. Random, 95% Cl	M-H. Random, 95% Cl	Study or Subgroup 2.5.1 < 6 months					Valght	Hel, Random, 95% Cl	M-H. Random, 91	2%.GL
insen2016		31	1.0	11	14.8%	0.8810.49, 1.552		Musharral 2017		40	21	40	11.8%	0.43 (0.22, 0.82)		
ajak2011		24	11	24	5.1%	0.36 (0.13, 0.98)		Subtotal (05% CI)		40			11.0%	0.43 [0.22, 0.82]	-	
btotal (96% CI)		35	11	35	19.9%	0.61 [0.24, 1.58]	-	Total events			21	-		area forest orast		
tal events	11	35	19	22	10.075	even formet unsel		Heterogeneity: Not app	distantia .		21					
terogeneity: Tau ^a = 0. st for overall effect: Z	31; Chi# = 2			0.09%	r = 65%			Test for overall effect:		= 0.01)						
								2,5.2 6 months	- 65	125	- 27	82	10.000	17100111101117		
1.2 > 800IU/d	23 2				1000			Arahi2014	4	64	5	66	3.2%	0.82 [0.23, 2.93]		
stro2014		201		207	23.2%	0.78 [0.50, 1.22]		Jensen2016	7	11	8		14.8%	0.88 [0.49, 1.56]		
btotal (95% CI)		201		207	23.2%	0.78 [0.50, 1.22]		Majak2011	. 4	24	11	24	5.1%	0.36 [0.13, 0.96]		
al events	28		37					Mubén2017	<u></u>	53	0	53	0.5%	3.00 [0.12, 72.02]		
terogeneity: Not apple								Subtotal (95% CI)		152		154	23.6%	0.73 [0.45, 1.20]		
st for overall effect: Z		7.28)						Total events Heteropeneity: Tau ² = Test for overall effect.			-3 (P =	0.36): P	= 6%			
sh2014	4	64		66	3.2%	0.82 (0.23, 2.93)		Total of Overlas effect.	to fr							
artineau2015		125		125	41.3%	0.82 (0.60, 1.14)	-	2.5.3 > 12 months								
arbneau2015 asharraf 2017	82	40	21	40	41.3%	0.43 (0.22, 0.62)		Castro2014	28	201	37	207	23.2%	0.78 (0.50, 1.22)		
usharral 2017 uben2017		40	0	53	0.5%	3.00 [0.12, 72.02]		Martineau2015	42	125	51		41.3%	0.62 [0.60, 1.14]		
btotal (95% CI)	- 18 M	282		284	56.0%	0.70 [0.46, 1.06]	•	Subtotal (95% CI)	**	326	31		64.5%	0.81 [0.62, 1.05]		
and the second	56		77			and forest stand	-	Total events	70		88			man forget stant	2.5	
	05; Chi* = 3.			0.27);	P = 24%			Heterogeneity: Tau* = Test for overall effect:	0.00; Chi* =		= 1 (P =	0.84); P	= 0%			
sterogeneity: Tau* = 0.	= 1.69 (P =															
stal events eterogeneity: Tau* = 0. est for overall effect: Z otal (95% CI)		518		526	100.0%	0.73 (0.58, 0.92)	•	Total (95% CI)		518		526 1	00.0%	0.73 [0.58, 0.92]	•	
eterogeneity: Tau* = 0. est for overall effect: Z otal (95% CI)		518		526	100.0%	0.73 [0.58, 0.92]	•	Total (95% CI) Total events	95	518	133	526 1	00.0%	0.73 [0.58, 0.92]	•	
sterogeneity: Tau* = 0. st for overall effect: Z	95		133			0.73 [0.58, 0.92]	• 0.01 0.1 1 10 1	Total (95% CI) Total events Heterogeneity: Tau ² =	95 0.01: Chi ² =		133 = 6 (P = 1			0.73 [0.58, 0.92]	01 0.1 1	10

Figure 6 Pooled relative risk for the subgroup analyses of asthma exacerbation (Panel A: subgroup analysis by baseline status of vitamin D; Panel B: subgroup analysis by different ages; Panel C: subgroup analysis by doses of vitamin D; Panel D: subgroup analysis by durations of vitamin D).

3.4.3. Asthma control test (ACT) scores

Three studies [13,17,27] provided data on ACT scores. The pooled data indicated there was no significant difference between vitamin D and placebo groups (MD: 0.80,95%Cl (-2.61, 4.22), with high heterogeneity (P = 0.0006, $I^2 = 86\%$)) (Table.4).

3.4.4. Fractional exhaled nitric oxide (FeNO)

Data on FeNO were available in three studies [27-29]. There was no significant difference between the two groups in terms of the effect on FeNO (MD: 1.86,95%Cl (-4.59, 8.32), without heterogeneity (P = 0.88, $I^2 = 0$)) (Table 4).

3.4.5. Interleukin-10(IL-10)

Four studies [13,26,29,33] provided data on IL-10. Because of the considerable differences in means among included trials, we chose the SMD with 95% CI as the pooled statistic. No difference was found between vitamin D and placebo groups regarding the effect on IL-10 (SMD: 0.46, 95% CI (-0.44, 1.36), with high heterogeneity (P < 0.0001, $I^2 = 86\%$)) (Table 4).

3.4.6. Safety

Six studies [12-14,16,28,32] investigated the incidence of adverse events. The pooled analysis showed no significant difference between groups regarding the rate of any serious adverse events (RR 0.87, 95% CI (0.41,1.81), without heterogeneity (P = 0.61, $I^2 = 0$)) (Table 4).

Outcome	Studies	N	Estimate	Effect(95%CI)	I ² %(P)
ACT scores	13,17,28	395	MD	0.16 (-2.62, 2.30)	81% (0.005)
FeNO	28-30	331	MD	1.86 (-4.59, 8.32)	0% (0.88)
IL-10	13,27,30,35	157	SMD	0.46 (-0.44, 1.36)	86% (0.0001)
Adverse event	12-14,16,29,34	714	RR	0.87 (0.41,1.81)	0% (<mark>0.61</mark>)

CI = confidence interval; ACT = asthma control test; IL-10 = interleukin-10; FeNO = fractional exhaled nitric oxide; MD = mean difference; SMD

= Standardized mean difference; RR = risk ratio; N = number of subjects.

Table 4 Effect of vitamin D supplementation vs placebo on different asthma outcomes.

3.4.7. Sensitivity Analysis

Sensitive analysis of primary outcomes was conducted by STATA (12.0) software, the findings showed that our results were consistent with the full analysis for all endpoints after excluding each individual study (Table 5).

Outcome	Imputing coefficient	Effect estimate (95% CI)
FEV ₁ %	-0.639	(-5.414, 4.136)
	2.013	(-2.409, 6.435)
Exacerbation	0.671	(0.489, 0.919)

	0.790	(0.629, 0.993)
ACT scores	-1.549	(-5.168, 2.070)
	0.970	(-1.222, 3.163)
FeNO	1.284	(-5.739, 8.307)
	5.054	(-8.926,19.034)
IL-10	0.054	(-0.571, 0.680)
	0.820	(-0.060, 1.699)
Adverse events	0.738	(0.343, 1.590)
	1.084	(0.104,11.260)

 $CI = confidence interval; FEV_1\% = predicted percentage of forced expiratory volume in first second; ACT = asthma control test; IL-10 = interleukin-10; FeNO = fraction of exhaled nitric oxide$

 Table 5
 Sensitivity analysis with highest and lowest correlation coefficients.

4. Discussion:

In this meta-analysis, fourteen studies demonstrated that vitamin D supplementation for the management of asthma was associated with a lower rate of exacerbation. It had no association with FEV₁%, ACT scores, FeNO, IL-10 and adverse events. In addition, the subgroup analyses of primary outcomes suggested that vitamin D supplementation would not be of help in all patients with bronchial asthma but in a certain group of patients those with vitamin D insufficiency at baseline.

Subgroup analysis of different baseline status of vitamin D was performed according to the Endocrine Society that defined vitamin D deficiency and insufficiency as a 25(OH)D < 30ng/ml [34]. It revealed that vitamin D supplementation was associated with a protective effect of exacerbation in participants with vitamin D insufficiency. However, there was only one study in the subgroup of patients with vitamin D sufficiency, and it suggested that there was a significant improvement of vitamin D supplementation upon asthma exacerbation. Nevertheless, it was considered insufficient to judge the positive effect of vitamin D supplementation for patients with vitamin D sufficiency. It was also associated with FEV₁% improvement in patients with air limitations and vitamin D insufficiency. With regards to different ages, we found that vitamin D supplementation might be associated with a lower rate of exacerbation and an improved pulmonary function in adults, but it did not have such positive effect on children. The small number of trials included children have a lower statistical power to extend the findings to all children. The probable explanation for the negative effect on children may be that, pulmonary function related outcomes were reported by three studies [13,31,33] in children. Its baseline status of FEV₁% was much greater than the patients in studies with adults. As a result, it left little room for improvement in pulmonary function. Another possible explanation may be that negative results were driven by varied baseline of vitamin D status among patients in the studies with children. Inversely, patients were all vitamin D insufficiency was associated with current asthma and wheeze in children as well as current asthma in adults [35]. Moreover, our subgroup analyses did not provide evidence about optimum doses and duration of vitamin D supplementation. The subgroup analysis of co-medicines was not performed due to unavailability of suitably disaggregated data.

There is plenty of evidence to support our results that vitamin D acts on the cells of the innate and adaptive immune systems as well as on structural cells in the airways, with its deficiency promoting inflammation and its supplementation alleviating these effects [3.4.6]. Our results are consistent with what many [36-39] have suggested that vitamin D supplementation had the capacity to reduce asthma exacerbations and improve asthma control, especially in patients with severe asthma and low vitamin D status. It is more readily explicable, based on the principle that people who are the most deficient in a micronutrient will be the most likely to respond to its replacement. However, our results may be inconsistent with other studies entirely. A recently cross-sectional study [40] found no association between vitamin D status and markers of asthma severity or control in adults. The potential explanation of inconsistent results was that the majority of including participants were adults with generally better symptom control. It also confirmed by another cross-sectional study [41] that the incidence of severe vitamin D insufficiency was high.

So far, six meta-analyses incorporating data from trials of vitamin D for the management of asthma have been done. Compared with them, our meta-analysis has several strengths. First, additional five studies were included in the current meta-analysis. Thus, the merging effect measures were more meaningful for our outcomes. Five studies were excluded, which were included in prior meta-analyses [20-22], one [42] was to detect steroid-induced bone loss in adult patients with asthma, another [43] was a randomized, two-period crossover trial with run-in and washout periods, which recruited different populations. In addition, three studies [44-46] did not meet our inclusion criteria for solely patients with asthma. Second, former meta-analysis failed to detect the source of heterogeneity and influence factors owing to the small number of remaining studies within each subcategory. In present meta-analysis, subgroup analyses were stratified by baseline of FEV₁%, 25(OH)D level, ages, different doses and durations of vitamin D supplementation. High heterogeneity of outcome in pulmonary function was resolved by subgroup analyses as well. These analyses make the results more meaningful for clinical decisions of asthma treatment. In view of the small number of patients in the second outcomes, sampling error was probably the main reason for the heterogeneity. Third, a sensitivity analysis on outcomes generated similar results, which indicated that results of the present meta-analysis were robustness.

Our meta-analysis also has several limitations. First, there is considerable variation in the definition of exacerbation. Except two studies [17, 30], all of studies presented the definition of asthma exacerbation. However, there was no significant heterogeneity in the outcome of exacerbation. Second, our meta-analysis included studies varied in relation to the study population, control medicines of asthma, duration of treatment, which might contribute to potential confounders for accurate inclusions. Consequently, we conducted subgroup analyses according to these factors and performed analysis using a random-effect model to avoid type \Box error. Confidence intervals for the average intervention effect would be wider and corresponding claims of statistical significance would be more conservative. Equally, the uncertainty is greater. Third, it was limited for our study to permit the funnel plot or meta-regression to assess the publication bias and potential influencing factors. Fourthly, our meta-analysis incorporated evidence from a relatively small number of studies and the finding was based primarily on results of trials conducted in patients with stable asthma. Therefore, it should not be generalized to patients with acute asthma. Finally, small sample sizes, clinical heterogeneity, or a combination of above factors' controversy have emerged among results of numerous studies, besides, optimal dosage and duration of vitamin D necessary for good control of asthma symptoms are yet unknown. All these aspects reinforce the need to perform larger, well designed randomized controlled trials to clarify causality for treatment of asthma and vitamin D supplementation.

In conclusion, our meta-analysis elucidated that vitamin D supplementation played a role in reducing the rate of asthma exacerbation, particularly in patients with vitamin D insufficiency. Additionally, it also had an improvement on FEV₁% in patients with air limitation and vitamin D insufficiency. Through the assessment for ACT scores, FeNO and IL-10, vitamin D supplementation was non-inferior to placebo. As a potential therapeutic option, vitamin D supplementation represents a low-cost, low-risk method to treat and control asthma. Therefore, larger and well-designed RCTs are required to evaluate the role of vitamin D in identical medication dose and administration duration of asthma.

Funding source

The funding for this study did not receive any specific grant from funding angencies in the public, commercial, or not-for-profit sectors.

Conflicts of interest

None

Acknowledgements

Role of authors:

Mingming Wang and Gang Cheng were engaged in design, interpretation of data, statistical analyses and drafting of the manuscript.

Cairu Wang and Yue Xiao were responsible for data extraction, statistical analyses, interpretation of data and administrative and technical support.

Meicen Liu and Meijuan Zou were responsible for conception and critical revision of the manuscript.

References

- [1] Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA), Available on <u>www.ginasthma.org</u>; Update 2018
- [2] B.M. Brumpton, A. Langhammer, A.H. Henriksen, et al., Serum 25-hydroxyvitamin D, vitamin D supplement and asthma control: The HUNT study., Respir. Med. 136 (2018) 65–70. https://doi.org/10.1016/j.rmed.2018.01.017.
- E.H. Mann, E.S. Chambers, P.E. Pfeffer, et al., Immunoregulatory mechanisms of vitamin D relevant to respiratory health and asthma., Ann. N. Y. Acad. Sci. 1317 (2014) 57–69. https://doi.org/10.1111/nyas.12410.
- S. Korn, M. Hubner, M. Jung, et al., Severe and uncontrolled adult asthma is associated with vitamin D insufficiency and deficiency., Respir. Res. 14 (2013) 25. https://doi.org/10.1186/1465-9921-14-25.
- [5] A.A. Litonjua, Childhood asthma may be a consequence of vitamin D deficiency., Curr. Opin. Allergy Clin. Immunol. 9 (2009) 202–207. https://doi.org/10.1097/ACI.0b013e32832b36cd.
- [6] R. Cassim, M.A. Russell, C.J. Lodge, et al., The role of circulating 25 hydroxyvitamin D in asthma: a systematic review., Allergy. 70 (2015) 339–354. https://doi.org/10.1111/all.12583.
- [7] E. Xystrakis, S. Kusumakar, S. Boswell, et al., Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients, J. Clin. Invest. 116 (2006) 146–155. https://doi.org/10.1172/JCI21759.146.
- [8] S.D. Brown, H.H. Calvert, A.M. Fitzpatrick, Vitamin D and asthma., Dermato-Endocrinology. 4 (2012) 137–145. https://doi.org/10.4161/derm.20434.
- [9] D.A. Searing, D.Y.M. Leung, Vitamin D in atopic dermatitis, asthma and allergic diseases., Immunol. Allergy Clin. North Am. 30 (2010) 397–409. https://doi.org/10.1016/j.iac.2010.05.005.
- [10] P.E. Pfeffer, C.M. Hawrylowicz, Vitamin D in Asthma: Mechanisms of Action and Considerations for Clinical Trials., Chest. 153 (2018) 1229–1239. https://doi.org/10.1016/j.chest.2017.09.005.
- S.C. Hall, D.K. Agrawa, Vitamin D and Bronchial Asthma: An overview of the last five years, Clin Ther. 39 (2017) 917–929. https://doi.org/10.1016/j.clinthera.2017.04.002.
- [12] A.M. Ali, S. Selim, M.M. Abbassi, et al., Effect of alfacalcidol on the pulmonary function of adult asthmatic patients: A randomized trial, Ann. Allergy, Asthma Immunol. 118 (2017) 557–563. https://doi.org/10.1016/j.anai.2017.02.014.
- [13] C.P. Kerley, K. Hutchinson, L. Cormican, et al., Vitamin D₃ for uncontrolled childhood asthma: A pilot study, Pediatr. Allergy Immunol. 27 (2016) 404–412. https://doi.org/10.1111/pai.12547.
- [14] A. Nageswari, G. Prathiksha, M. Rajanandh, Effectiveness of vitamin D3 in severe persistent asthmatic patients: A double blind, randomized, clinical study, J. Pharmacol. Pharmacother. 6 (2015) 142. https://doi.org/10.4103/0976-500X.162022.
- [15] M. M.U., S. G.A., M. M.U., et al., Role of vitamin D in prevention of acute exacerbation of bronchial asthma in adults, J. Postgrad. Med. Inst. 31 (2017) 310–313. http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L617767557.
- [16] M.E. Jensen, G. Mailhot, N. Alos, E. Rousseau, et al., Vitamin D intervention in preschoolers with viral-induced asthma (DIVA): A pilot randomised controlled trial, Trials. 17 (2016) 4–11. https://doi.org/10.1186/s13063-016-1483-1.
- [17] R.A. MurciaSalud, Efficacy of Calcifediol Supplementation in Asthma Control in Asthmatic Patients With Vitamin D Deficiency (ACViD), NCT:02805907 Available on: https://www.clinicaltrials.gov/ct2/show/NCT02805907?cond=ACVID&rank=1; Update 2017 [accessed 16.6.17]
- [18] A. Martineau, C. Cates, M. Urashima, et al., Vitamin D for the management of asthma, Cochrane Database Syst. Rev. (2016). https://doi.org/10.1002/14651858.CD011511.pub2.www.cochranelibrary.com.
- [19] M.M. Fares, L.H. Alkhaled, S.M. Mroueh, et al., Vitamin D supplementation in children with asthma: A systematic review and meta-analysis, BMC Res. Notes. 8 (2015) 10–19. https://doi.org/10.1186/s13104-014-0961-3.
- [20] B.D. Riverin, J.L. Maguire, P. Li, Vitamin D Supplementation for Childhood Asthma: A Systematic Review and Meta-Analysis., PLoS One. 10 (2015) 0136841. https://doi.org/10.1371/journal.pone.0136841.

- [21] J. Luo, D. Liu, C.-T. Liu, Can Vitamin D Supplementation in Addition to Asthma Controllers Improve Clinical Outcomes in Patients With Asthma? A Meta-Analysis., Medicine. 94 (2015) 2185. https://doi.org/10.1097/MD.00000000002185.
- [22] S. Pojsupap, K. Iliriani, T.Z.A.L. Sampaio, et al., Efficacy of high-dose vitamin D in pediatric asthma: a systematic review and meta-analysis., J. Asthma. 52 (2015) 382–390. https://doi.org/10.3109/02770903.2014.980509.
- [23] D.A. Jolliffe, L. Greenberg, R.L. Hooper, et al., Vitamin D supplementation to prevent asthma exacerbations: a systematic review and meta-analysis of individual participant data., Lancet. Respir. Med. 5 (2017) 881–890. https://doi.org/10.1016/S2213-2600(17)30306-5.
- [24] A. Liberati, D.G. Altman, J. Tetzlaff, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration., BMJ. 339 (2009). https://doi.org/10.1136/bmj.b2700.
- [25] J.P.T. Higgins, S.G. Thompson, J.J. Deeks, et al., Measuring inconsistency in meta-analyses., BMJ. 327 (2003) 557–560. https://doi.org/10.1136/bmj.327.7414.557.
- [26] R.S. Abbas, M.K. Abdulridha, M.A. Shafek, Clinical Evaluation of Potential Anti-Inflammatory Effect of Vitamin D3 Adjuvant Therapy for Chronic Asthma in Iraqi Patients, Int. J. Pharm. Pharm. Sci. 9 (2016) 139. https://doi.org/10.22159/ijpps.2017v9i1.15487.
- [27] A.R. Martineau, B.D. MacLaughlin, R.L. Hooper, et al., Double-blind randomised placebo-controlled trial of bolus-dose vitamin D3 supplementation in adults with asthma (ViDiAs), Thorax. 70 (2015) 451–457. https://doi.org/10.1136/thoraxjnl-2014-206449.
- [28] J.C. De Groot, E.N.H. Van Roon, H. Storm, et al., Vitamin D reduces eosinophilic airway inflammation in nonatopic asthma, J. Allergy Clin. Immunol. 135 (2015) 670–675.e3. https://doi.org/10.1016/j.jaci.2014.11.033.
- [29] R. Bar Yoseph, G. Livnat, Z. Schnapp, et al., The effect of vitamin D on airway reactivity and inflammation in asthmatic children: A double-blind placebo-controlled trial, Pediatr. Pulmonol. 50 (2015) 747–753. https://doi.org/10.1002/ppul.23076.
- [30] S. Arshi, M. Fallahpour, M. Nabavi, et al., The effects of vitamin D supplementation on airway functions in mild to moderate persistent asthma, Ann. Allergy, Asthma Immunol. 113 (2014) 404–409. https://doi.org/10.1016/j.anai.2014.07.005.
- [31] P. Majak, M. Olszowiec-Chlebna, K. Smejda, et al., Vitamin D supplementation in children may prevent asthma exacerbation triggered by acute respiratory infection, J. Allergy Clin. Immunol. 127 (2011) 1294–1296. https://doi.org/10.1016/j.jaci.2010.12.016.
- [32] M. Castro, T.S. King, S.J. Kunselman, et al., Effect of Vitamin D₃ on Asthma Treatment Failures in Adults With Symptomatic Asthma and Lower Vitamin D Levels The VIDA Randomized Clinical Trial, Jama. 311 (2014) 2083. https://doi.org/10.1001/jama.2014.5052.
- [33] P. Majak, B. Rychlik, I. Stelmach, The effect of oral steroids with and without vitamin D3 on early efficacy of immunotherapy in asthmatic children, Clin. Exp. Allergy. 39 (2009) 1830–1841. <u>https://doi.org/10.1111/j.1365-2222.2009.03357.x</u>.
- [34] M.F. Holick, N.C. Binkley, H.A. Bischoff-ferrari, et al., Treatment and Prevention of Vitamin D Deficiency : an Endocrine Society Clinical Practice Guideline, 96 (2011) 1911–1930. doi:10.1210/jc.2011-0385.
- [35] Y. Han, E. Forno, J.C. Celed, et al., Vitamin D Insufficiency and Asthma in a US Nationwide Study, J. Allergy Clin. Immunol. Pract. (2016) 1–8. doi:10.1016/j.jajp.2016.10.013.
- [36] M.Z.M. Babar, M. Hussain, S.A. Majeed, Vitamin D supplementation improves FEV₁ in patients of Bronchial Asthma., Pakistan J. Med. Sci. 33 (2017) 1144–1147. https://doi.org/10.12669/pjms.335.12990.
- [37] Q. Kang, X. Zhang, S. Liu, et al., Correlation between the vitamin D levels and asthma attacks in children: Evaluation of the effects of combination therapy of atomization inhalation of budesonide, albuterol and vitamin D supplementation on asthmatic patients., Exp. Ther. Med. 15 (2018) 727–732. https://doi.org/10.3892/etm.2017.5436.
- [38] P.E. Pfeffer, Targeting the exposome: does correcting vitamin D deficiency have potential to treat and prevent asthma, Expert Rev. Clin. Immunol. 14 (2018) 241–243. https://doi.org/10.1080/1744666X.2018.1440207.
- [39] N.S. Ali, K. Nanji, A Review on the Role of Vitamin D in Asthma, Cureus. 9 (2017). https://doi.org/10.7759/cureus.1288.
- [40] D.A. Jolliffe, K. Kilpin, B.D. MacLaughlin, et al., Prevalence, determinants and clinical correlates of vitamin D deficiency in adults with inhaled corticosteroid-treated asthma in London, UK., J. Steroid Biochem. Mol. Biol. 175 (2018) 88–96. https://doi.org/10.1016/j.jsbmb.2016.11.004.
- [41] E. Janeva-Jovanovska, D. Dokic, B. Jovkovska-Kaeva, et al., Relationship between Vitamin D, Inflammation and Pulmonary function In Patients with Severe Uncontrolled Asthma., Open Access Maced. J. Med. Sci. 5 (2017) 899–903. https://doi.org/10.3889/oamjms.2017.190.

- [42] H. Worth, D. Stammen, E. Keck, Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and a diphosphonate, Am. J. Respir. Crit. Care Med. 150 (1994) 394–397. https://doi.org/10.1164/ajrccm.150.2.8049820.
- [43] A.J. Schou, C. Heuck, O.D. Wolthers, Does Vitamin D Administered to Children with Asthma Treated with Inhaled Glucocorticoids Affect Short-Term Growth or Bone Turnover?, Pediatr. Pulmonol. 36 (2003) 399–404. https://doi.org/10.1002/ppul.10379.
- [44] S. Baris, A. Kiykim, A. Ozen, et al., Vitamin D as an adjunct to subcutaneous allergen immunotherapy in asthmatic children sensitized to house dust mite, Allergy Eur. J. Allergy Clin. Immunol. 69 (2014) 246–253. https://doi.org/10.1111/all.12278.
- [45] M. Urashima, T. Segawa, M. Okazaki, et al., Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren, Am. J. Clin. Nutr. 91 (2010) 1255–1260. https://doi.org/10.3945/ajcn.2009.29094.
- [46] E. Lewis, C. Fernandez, A. Nella, et al., Relationship of 25-hydroxyvitamin D and asthma control in children, Ann. Allergy, Asthma Immunol. 108 (2012) 281–282. <u>https://doi.org/10.1016/j.anai.2012.01.003</u>.

A CERTICAL

						Intervention			
Author Year	Country	N	participants	Drug	Dose	Co-intervention	Duration (mo)	Follow-up (mo)	Outcomes
Ali2017[12]	Egypt	60	Intermittent to severe persistent asthma	ALF	lmg/d	Intermittent: inhaler 100µg salbutamol Moderate: 12 mg formoterol/ 400 mg theophylline, twice daily severe asthma (>50%): high dose beclomethasone	4	1, 2, 3, 4	FEV ₁ %, AdE
Musharraf 2017[15]	Pakistan	80	Asthma Diagnosed for ≥ 1 year with VD < 30 ng/ml.	VD	50,000IU/2w	ICS (Salmeterol/fluticasone 25/250µg twice daily) + Montelukast 10mg	3	3	AE
ABBAS2017[26]	Iraq	44	Asthma	VD	2000IU/d	Conventional therapy (no description)	3	3	FEV ₁ %, IL-10
Rubén2017[17]	Spain	106	Asthma with VD < 30 ng/ml.	CAL	16,000IU/w	None	6	6	AE, ACT
Jensen2016[16]	Canada	22	Viral-induced asthma	VD	100,000 IU	Vitamin D ₃ 400IU/d	6	0.3, 3, 6	AE, AdE,
Kerley2016[13]	Ireland	39	Uncontrolled asthma	VD	2000IU/d	Conventional therapy (no description)	3.75	3.75	FEV ₁ %, ACT, IL-10, AdE
Martineau2015[27]	UK	250	Asthma treated with ICS	VD	120000 IU/2mo	None	12	2, 6, 12	FEV ₁ %, ACT, FeNO, AE
de Groot2015[28]	Netherlands	44	Nonatopic asthma	VD	400,000 IU	Conventional therapy (no description)	1.5	0.25, 1.5	FEV ₁ %, FeNO _, AdE
Nageswari2015 [14]	India	141	Severe persistent asthma	VD	1000 IU/d	ICS (budesonide 800µg + formoterol 24µg)/d	6	1, 2, 3, 4, 5, 6	AdE
Castro2014[32]	US	408	Asthma with VD < 30 ng/ml	VD	100000 IU once then 4000 IU/d	Inhaled ciclesonide 320µg/d + levalbuterol	7	7	AE, AdE
Yoseph2014[29]	Israel	38	Mild asthma with VD < 30	VD	14,000 IU/w	None	1.5	1.5	IL-10, FeNO

Arshi2014[30]	Iran	130	Mild to moderate persistent asthma	VD	100000IU once then 50000IU/w	ICS (budesonide/budesonide+ formoterol)	6	2, 6	FEV ₁ %, AE,
Majak2011[31]	Poland	48	Newly diagnosed asthma and sensitive only to house dust	VD	500 IU/d	Inhaled budesonide 800µg/d	6	2,4,6	FEV ₁ %, AE,
Majak2011[51]	Toland	40	mites	VD	500 10/4	initialed bacesonide boopgra	0	2,7,0	1 L v 1/0, AL,
			IgE - dependent asthma with regular symptoms requiring long			Ś			
Majak2009[33]	Poland	36	- term treatment with ICSs, and	VD	1000IU/d	prednisone 20mg	3,12	3, 12	FEV ₁ %, IL-10
			a disease duration of at least 2						
			years.						

N = number; mo = month; ALF = alfacalcidol; FEV1% = predicted percentage of forced expiratory volume in first second; AdE = adverse events; w = week; VD = vitamin D; ICS = inhaled corticosteroids; AE = asthma exacerbation; IL-10 =

CERTER

interleukin-10; CAL= calcifediol; ACT = asthma control test; FeNO = fractional exhaled nitric oxide.

ng/ml

Table 1 Details of included studies.

Author Year	-	years) n (SD)	Sex (Female%)	FEV Mean		FeNO Mean			Scores		(pg/ml) n (SD)		D (ng/ml) n (SD)
	I	C		I	C	I	C	I	C	I	C	I	C
Ali2017[12]	43(10.25)	48(11.25)	68.3	57(20.25)	57(20.25)	NM	NM	NM	NM	NM	NM	18(10.33)	18.5(12.8)
Musharraf2017 [15]	29.70(7.74)	29.43(8.47)	42.5	NM	NM	NM	NM	NM	NM	NM	NM	<30	<30
ABBAS2017[26]	41.4 (13.6)	40.75(17.31)	75.0	43.92(20.36)	50.90(16.04)	NM	NM	NM	NM	37.0(8.64)	29.5(5.17)	8.90(6.82)	6.33(4.64)
Rubén2017[17]	54.57(15.83)	56.61(15.00)	77.7	NM	NM	NM	NM	17.71(4.54)	19.02(4.59)	NM	NM	<30	<30
Jensen2016[16]	2.2 (1.19)	3.1 (1.33)	63.6	NM	NM	NM	NM	NM	NM	NM	NM	24.86 (2.51)	27.27
Kerley2016[13]	10(4.44)	7(2.22)	38.5	105(16.3)	96 (10.37)	NM	NM	19(2.96)	17(3.48)	111	110	20.45	20.45
Martin	40 4(14 9)	46 4 (12 8)	56.4	82.0 (19.7)	81.0 (20.4)	28 1/20 1)	27.0(26.0)	10.2(2.0)	18.0.(2.0)	(27.41)	(47.41)	(7.43) 19.97	(8.92) 19.81
Martineau2015[27]	49.4(14.8)	46.4 (13.8)	56.4	82.0 (18.7)	81.0 (20.4)	38.1(29.1)	37.0(26.0)	19.2(3.9)	18.9 (3.9)	NM	NM	(10.1) 24.06	(9.7) 22.85
de Groot2015[28]	59(9.7)	53.6(16.7)	40.9	99.1(15.7)	97.6(18.1)	24(12.59)	33(38.52)	NM	NM	NM	NM	(9.27)	(8.91)
Nageswari2015 [14]	58.46(8.6)	57.18(9.2)	52.1	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM
Castro2014[32]	39.9(13.1)	39.5(12.7)	68.1	80.7(13.8)	80.5 (14.2)	NM	NM	NM	NM	NM	NM	19 (10.37)	18.8 (11.85)
Yoseph2014[29]	13.5(3.6)	12.4(3.6)	36.8	NM	NM	36.6(39.1)	58.6(54.7)	NM	NM	0.95(0.19)	0.96(0.19)	20.8(6.5)	20.0(7.1)

Arshi2014[30]	24.40(9.63)	28.64(9.78)	60.8	69.1(9.39)	71.2(7.46)	NM	NM	NM	NM	NM	NM	23.82	24.02
AISII2014[50]	24.40(9.03)	28.04(9.78)	00.8	09.1(9.39)	/1.2(7.40)		19191	INIVI	INIVI	INIVI	INIM	(16.33)	(16.45)
M : 10011/211	10.0 (2.2)	11.1 (2.2)	22.2	04 4(12)	00.7(10)						224	36.1	35.1
Majak2011[31]	10.8 (3.2)	11.1 (3.3)	33.3	94.4(13)	98.7(12)	NM	NM	NM	NM	NM	NM	(13.9)	(16.9)
Majak2009[33]	6-12	6-12	38.9	95.2(4.8)	93.4(3.2)	NM	NM	NM	NM	80.0(20.0)	75.3(25.9)	32.0(3.1)	31.3(3.4)
Wajak2009[55]	0-12	0-12	30.9	93.2(4.8)	95.4(5.2)	INIVI	14141	INIM	INIVI	80.0(20.0)	13.3(23.9)	32.0(3.1)	51.5(5.4)

- astma c. FEV1% = predicted percentage of forced expiratory volume in first second; FeNO = fraction of exhaled nitric oxide; ACT = asthma control test; IL-10 = interleukin-10; 25(OH)D = 25-hydroxyvitamin D; SD = standard derivation; NM = not

mentioned.

 Table 2
 Baseline characteristics of patients in the 14 studies included.

Outcome	Study	Risk of	Inconsistency	Indirectness	Imprecision	Publication bias	Quality of
outcome	design	bias	meensisteney	manootnoss	Imprecision	r ucheution chus	evidence
FEV ₁ %	RCT	Serious ¹	Very serious ²	No serious	Serious ³	Serious ⁴	Very Low
Subgroups:							
А	RCT	Serious ¹	No serious	No serious	Serious ³	No Serious	Low
В	RCT	Serious ¹	Serious ²	No serious	Serious ³	No Serious	Low
С	RCT	Serious ¹	No serious	No serious	Serious ³	No Serious	Low
Adults	RCT	Serious ¹	Serious ²	No serious	serious ³	No Serious	Low
Children	RCT	Serious ¹	Serious ²	No serious	Very serious ³	Serious	Very Low
Exacerbation	RCT	Serious ¹	No serious	No serious	Serious ³	Serious ⁴	Very Low
Subgroups:							
D	RCT	Serious ¹	No serious	No serious	Serious ³	No Serious	Low
E	RCT	Serious ¹	No serious	No serious	Serious ³	Serious ⁴	Very Low
Adults	RCT	Serious ¹	No serious	No serious	Serious ³	No Serious	Low
Children	RCT	Serious ¹	Serious ²	No serious	Very serious ³	Serious ⁴	Very Low
ACT scores	RCT	Serious ¹	Very serious ²	No serious	Very serious ³	No Serious	Very Low
FeNO	RCT	Serious ¹	No serious	No serious	Very serious ³	No Serious	Very Low
IL-10	RCT	Serious ¹	Very serious ²	No serious	Very serious ³	No Serious	Very Low
Adverse events	RCT	Serious ¹	No serious	No serious	Very serious ³	No Serious	Very Low

 $FEV_1\% =$ predicted percentage of forced expiratory volume in first second; RCT = randomized controlled trials; VD = vitamin D; ACT = asthma control test; FeNO = fractional exhaled nitric oxide; IL-10 = interleukin-10; A = subgroup of patients with air limitation and vitamin D insufficiency; B = subgroup of patients without air limitation and vitamin D insufficiency; C = subgroup of patients without air limitation and vitamin D sufficiency; D = subgroup of patients with

vitamin D insufficiency; E = subgroup of patients with vitamin D sufficiency.

¹ blinding method and selective reporting and other types of some included trials were not offered.

² Inconsistency were reported by moderate to high heterogeneity.

³ The total sample size is much less than OIS and the overall number of events was less than 300.

⁴ Publication bias were reported by incomplete outcome data.

 Table 3
 GRADE assessment of the quality of evidence for endpoints.

C

Outcome	Studies	Ν	Estimate	Effect(95%CI)	I ² %(P)
ACT scores	13,17,28	395	MD	0.16 (-2.62, 2.30)	81% (0.005)
FeNO	28-30	331	MD	1.86 (-4.59, 8.32)	0% (0.88)
IL-10	13,27,30,35	157	SMD	0.46 (-0.44, 1.36)	86% (0.0001)
Adverse event	12-14,16,29,34	714	RR	0.87 (0.41,1.81)	0% (0.61)

CI = confidence interval; ACT = asthma control test; IL-10 = interleukin-10; FeNO = fractional exhaled nitric oxide; MD = mean difference; SMD

= Standardized mean difference; RR = risk ratio; N = number of subjects.

 Table 4
 Effect of vitamin D supplementation vs placebo on different asthma outcomes.


Chillip Mark


Outcome	Imputing coefficient	Effect estimate (95% CI)
FEV ₁ %	-0.639	(-5.414, 4.136)
	2.013	(-2.409, 6.435)
Exacerbation	0.671	(0.489, 0.919)
	0.790	(0.629, 0.993)
ACT scores	-1.549	(-5.168, 2.070)
	0.970	(-1.222, 3.163)
FeNO	1.284	(-5.739, 8.307)
	5.054	(-8.926,19.034)
IL-10	0.054	(-0.571, 0.680)
	0.820	(-0.060, 1.699)
Adverse events	0.738	(0.343, 1.590)
	1.084	(0.104,11.260)

 $CI = confidence \ interval; FEV_{1}\% = predicted \ percentage \ of \ forced \ expiratory \ volume \ in \ first \ second; \ ACT = asthma \ control \ test; \ IL-10 = asthma \ respectively \ respectivel$

interleukin-10; FeNO = fraction of exhaled nitric oxide

 Table 5
 Sensitivity analysis with highest and lowest correlation coefficients.





Study or Subgroup ABBAS2017 Al2017 Arshi2014 de Groot2015 Kerley2016 Majak2009 Majak2011 Martineau2015 Total (95% CI) Heterogeneity: Tau ^a = Test for overall effect:	Mean 19.12 7.5 13.7 -1.7 -3.5 0.7 4.6 -1.4	20.52 8.25 9.31 15.7 5.037 4.49 12.16 19.95	Total Mea 24 17.9 32 -1. 64 5. 22 -3. 6 4. 18 1. 24 4. 125 315 09, df = 7 (I	5 15.52 5 8.5 2 7.5 6 17.62 5 6.07 4 2.86 4 12.05 0 20.603	20 28 66 22 8 18 24 125 311	Weight 8.3% 14.2% 15.2% 8.9% 12.7% 15.5% 11.7% 13.4%	Mean Difference IV. Random, 95% CI 1.17 [-9.49, 11.83] 9.00 [4.75, 13.25] 8.50 [5.59, 11.41] 1.90 [-7.96, 11.76] -8.00 [-13.83, -2.17] -0.70 [-3.16, 1.76] 0.20 [-6.65, 7.05] -1.40 [-6.43, 3.63] 1.55 [-2.83, 5.93]	Mean Difference IV. Random. 95% CI

A Experimental Control	Mean Difference	Mean Difference	B Experimental Control	Mean Difference Mean Difference
Backy of Ruleprisus Main 50. Total. Mean 60. Total. Mean 12.1 Vitamio 1-O-Signel with all initianation(FEV15-4006) (FEV15-6006) 30. All initianation (FEV15-6006) (FEV15-6006) 20. All initianation (FEV15-6006) (FEV15-6006) 20. All initianation (FEV15-6006) (FEV15-6006) (FEV15-6006) 20. All initianation (FEV15-6006) (FE	N 1.17 [-9.49, 11.83] S 9.00 [4.75, 13.25] N 8.50 [5.59, 11.41]	IV. Bandem. 92% CI	Bitudy co Rubergroup Mean SD. Total. Mean SD. Total. Weight 1.3.1.4.0.016 19.12 20.52 24 17.95 15.52 20 8.3% ABDAT2017 19.12 20.52 24 17.95 15.52 20 8.3% ABDAT2 7.5 8.23 22 1.5 8.2 2.5 8.4 2.4 Amb2017 7.5 8.23 2.5 2.8 2.6 1.5 2.6 1.6 2.6 7.5 65 1.52% 2.6 1.6 1.6 1.6 1.5 1.6 1.6 2.7 7.6 1.5 1.6 1.5 1.6 1.6 1.7 1.6 1.7 1.6	Nr. Random. 82% CI Nr. Random. 82% CI 1.17 (404, 11.80) 000 (47, 13.28) 6.50 (55, 11.41)
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	% -1.40 [-6.43, 3.63]		Test for oversit effect. Z = 1.97 (P = 0.05) 1.3.2 Children Kendry2016 - 3.5 5.037 6 4.5 6.07 8 12.7% Majac2009 0.7 4.49 16 1.4 2.68 18 15.5% Majac201 4.6 12.16 24 4.4 12.05 24 11.7% Stutted (15% CI) 46 12.0 24 41.7% Stutted (15% CI) 45 24 4.4 12.0 24 11.7%	-0.70 [-3.16, 1.76]
$\label{eq:linearised} \begin{array}{cccc} 12.3\ \mbox{Unamin}\ D^{-3}Ong/ml \ \mbox{without air limitation}(PEV1X>B0X)) \\ Maja2000 & 0.7 & 4.60 & 18 & 1.4 & 2.66 & 18 & 15.5 \\ Maja2011 & 4.6 & 12.16 & 24 & 4.4 & 12.05 & 24 & 11.7 \\ Subtoat [65% C1] & 4.6 & 12.16 & 24 & 4.2 & 12.05 & 24 & 11.7 \\ Hoterogeneity: Fau* = 0.00; Ch* = 0.66, d= 1 (P=0.61); P=0.64 \\ Test for overall effect: Z=0.51 (P=0.61) \\ \end{array}$	% -0.70 [-3.16, 1.76] % 0.20 [-6.65, 7.05] % -0.60 [-2.91, 1.72]	•	Test for overall effect: Z = 1.09 (P = 0.27)	1.55 [-2.83, 5.83]
Total (95% CI) 315 311 100.0 Neterogenesity: Tar# = 30.49; Ch/# = 47.09; df = 7 (P < 0.0001); l* = 65%	-20	-10 0 10 20 Favours (control) Favours (accentmental)	: 	
C Experimental Control Bludy.or.Bubgroup Mean <u>BD Total Mean</u> <u>BD Total Weig</u> 1.4.1 <300 IU/d AU2017 7.5 8.25 32 -1.5 8.5 28 14.2	and the second second second second	Mean Difference IV. Random, 95% Cl	D Experimental Control	Mean Difference Mean Difference N. Random, 95% Cl IV. Random, 95% Cl 1.17 (-0.49, 11.63)
Majak2011 4.6 12.16 2.4 4.4 12.05 24 11.7 56 50:00101 56 50 52.5 1646rogonalty: Tay ⁴ = 30.26 Ch ² = 4.58, df = 1 (P = 0.03); P = 78% feat for overall effect. Z = 1.15 (P = 0.25) 1.4 2 2500 (Md	N. 0.20 (-6.65, 7.05) % 5.03 (-3.56, 13.61)	-	Al2017 7.5 8.25 32 -1.5 8.5 28 14.2%	9.00 [4.75, 13.25]
$\label{eq:approximate} \begin{array}{llllllllllllllllllllllllllllllllllll$	% 1.17 [-9.49, 11.83] % -8.00 [-13.83, -2.17] % -4.55 [-13.26, 4.16]	*	1.5.2 6 months Anal/2014 13.7 9.31 64 52 7.5 66 152% Maja/2011 4.6 12.16 24 4.4 12.05 24 11.7% Subtotal (\$9% C1) Heterogeneity: Tauf = 27.24; Chr = 4.78, df = 1 (P = 0.03); F = 17%	8.50 (5.59, 11.41) 0.20 (-8.65, 7.05) 4.98 (-3.09, 13.60)
1.4.3 intermittent high-does Anh2014 13.7 9.31 64 5.2 7.5 66 15.2 49 6002016 -1.7 15.7 22 3.9 Majel 2000 10.4 15.7 22 3.9 Majel 2000 0.7 4.4 18 1.4 26.6 18 1.5 26 12.5 13.4 Subtoal (95% CI) 1.4 19.95 125 0.20 12.5 1.5.2	% 1.90 [-7.96, 11.76] % -0.70 [-3.16, 1.76] % -1.40 [-6.43, 3.63]	+	Test for overall effect. Z = 1.21 (P = 0.23) 1.5.3 > 60 months Majarizado 0.7 4.48 1.8 1.4 2.9 0.7 4.48 1.8 1.43 2.6 1.8 1.5.5 %. Martineaco15 -1.4 1.9 125 2.000a1 (25: 13.4%. Subtolal (495 C0) 1.43 1.49 1.9 -0.61); I* - 0.41;	-0,70 [-3.16, 1.76] -1.40 [-4.43, 3.63] -8.84 [-3.04, 1.37]
Test for overall effect Z = 0.74 (P = 0.46) Total (95% CI) 315 311 100.0 Neterogenetity: Tau ⁴ = 30.49; Ch ² = 47.09, df = 7 (P < 0.00001); P = 65% Test for overall effect Z = 0.09 (P = 0.49)	% 1.55 (-2.83, 5.93) -100	-50 0 50 100	Test for overall effect Z = 0.74 (P = 0.46) Total (B5% CI) 315 311 100.0% Heterogeneity: Tau ² = 30.49; CN ² = 7.70, dl = 7 (P < 0.00001); P = 65%	1.55 (-2.63, 5.83)
		\sim		
(
Ç,				

Study or Subgroup Arshi2014 Castro2014 Jensen2016 Majak2011 Martineau2015 Musharraf 2017 Rubén2017 Total (95% CI) Total events Hoterogeneity: Tau ^a = Test for overall effect: 2	<u>Total</u> 64 201 11 24 125 40 53 518 = 6.31, df	5 37 8 11 51 21 0 133 = 6 (P =	Total 66 207 11 24 125 40 53 526	3.2% 23.2% 14.8% 5.1% 41.3% 11.8% 0.5%	Risk Ratio <u>M-H. Random, 95% Cl</u> 0.82 [0.23, 2.93] 0.78 [0.50, 1.22] 0.88 [0.49, 1.55] 0.36 [0.13, 0.98] 0.82 [0.60, 1.14] 0.43 [0.22, 0.82] 3.00 [0.12, 72.02] 0.73 [0.58, 0.92]	100
		8				

	Experiment	al Co	ntrol		Risk Ratio	Risk Ratio		В	Experim	iental	Contre	2		Risk Ratio	Risk Ratio	
dy or Subgroup	Eventa T	otal Even	ta Tota	Weight	M-H, Random, 95% Cl.	M-H, Random, 95%	CI	Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Random, 95% (CI M-H. Random, 95%	CI
1 Vitamin D<30ng/	ml							2.3.1 Adults								
N2014	4	64	5 66	3.2%	0.82[0.23, 2.93]			Arshi2014	4	64	5	66	3.2%	0.82 [0.23, 2.93		
tro2014			17 207	23.2%	0.78 [0.50, 1.22]			Castro2014	28	201	37	207	23.2%	0.78 [0.50, 1.22		
sen2016	7	11	8 11		0.88 [0.49, 1.55]			Martineau2015	42	125	51	125	41.3%	0.82 [0.60, 1.14		
tineau2015			51 125		0.82 [0.60, 1.14]											
harraf 2017			21 40		0.43 [0.22, 0.82]			Mushamaf 2017	9	40	21	40	11.8%	0.43 [0.22, 0.82		
						and the second se		Rubén2017	1	53	0	53	0.5%	3.00 [0.12, 72.02		
wn2017	- 1	53	0 53		3.00 [0.12, 72.02]	•		Subtotal (95% CI)		483		491	80.1%	0.75 [0.59, 0.95]	1 🕈	
total (95% CI)				94.9%	0.76 [0.61, 0.95]	•		Total events	84		114				· · · · · · · · · · · · · · · · · · ·	
al events	91		22					Heterogeneity: Tau ² =	= 0.00; Chi#	= 3.98, c	f=4(P=	0.41);	1" = 0%			
erogeneity: Tau ⁴ = 0			P = 0.52	: P=0%				Test for overall effect	Z = 2.39 (F	P = 0.021	지 말했다.	- 55				
t for overall effect: Z	= 2.38 (P =	0.02)							0000000	1-30%						
101217-202012-00	195							2.3.2 Children								
2 Vitamin D>30ng/	mi					10 million (10 mil		Jensen2016		11	8	11	14.8%	0.88 (0.49, 1.55		
jak2011	4		11 24		0.36 [0.13, 0.96]				1		11	24				
itotal (95% CI)		24	24	5.1%	0.36 [0.13, 0.98]	-		Majak2011	•	24	11		5.1%	0.36 [0.13, 0.98		
al events	4	14	11					Subtotal (95% CI)		35		35	19.9%	0.61 [0.24, 1.58]		
erogeneity: Not appl	icable							Total events	11		19					
t for overall effect: Z		0.05)						Heterogeneity: Tau ^a +	= 0.31; Chi#	= 2.82, d	f=1(P=	0.09);	P = 65%			
020202020202020202						53		Test for overall effect	Z = 1.02 (F	P=0.31)						
al (95% CI)		518	526	100.0%	0.73 [0.58, 0.92]	•										
al ovents	95	1			the freedom of	0.08		Total (95% CI)		518		526	100.0%	0.73 [0.58, 0.92]	1	
erogeneity: Tau* = 0				17 - 535				Total events	95		133					
t for overall effect: Z			P = 0.39	(r		0.01 0.1 1	10 100	Heterogeneity: Tau ^a =		- 6 31 4		0.303-	12 - 640		<u> </u>	+
t for subarous differ						Favours (experimental) Favours	[control]	Test for overall effect				0.34),	1 3.4		0.01 0.1 1	10
t for subdroup differ	encase una s	2.04. 01 =	110-10.	DI 1" = DI.	126										[experimental] [control]	
								Test for suboroup diff	erences: Ci	B*=0.1/	dr=10	= 0.63	 P = 0% 			
	Experiment	al Co	ntrol		Risk Ratio	Risk Ratio		D	Experime	intal	Control			Risk Ratio	Risk Ratio	
dy or Subaroup	Events T	otal Even	ts Total	Weight	M-H. Random, 95% Ci	M-H. Random, 95%	CI	Study or Subgroup	Events	Total E	vents To	stal W	eight M	H. Random, 95% Ci	M-H, Random, 95% Ci	61
1 < 800IU/d								2.5.1 < 6 months								
												40 1	1.8%			
1012016	7	11	8 11					Musharral 2017	9							
	1	11	8 11		0.88 [0.49, 1.55]			Musharraf 2017 Subtotal (95% CI)	9	40	21			0.43 [0.22, 0.82]	-	
ak2011	4	24	11 24	5.1%	0.36 [0.13, 0.98]			Subtotal (95% CI)	9		252		1.8%	0.43 [0.22, 0.82] 0.43 [0.22, 0.82]	•	
nsen2016 jak2011 btotal (95% CI)	4	24 35	11 24	5.1%				Subtotal (95% CI) Total events	9		21				•	
jak2011 btotal (95% CI) al events	7 4	24 35	11 24 35 19	5.1% 19.9%	0.36 [0.13, 0.98]	-		Subtotal (95% CI) Total events Heterogeneity: Not app		40	252				•	
jak2011 btotal (95% CI) al events lerogeneity: Tau* = 0	31; Chi+ = 2	24 35 82, df = 1 (11 24 35 19	5.1%	0.36 [0.13, 0.98]	-		Subtotal (95% CI) Total events		40	252				•	
jak2011 btotal (95% CI)	31; Chi+ = 2	24 35 82, df = 1 (11 24 35 19	5.1% 19.9%	0.36 [0.13, 0.98]	-		Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect.		40	252				•	
ak2011 stotal (95% CI) al events erogeneity: Tau ^a = 0 t for overall effect: 2	31; Chi+ = 2	24 35 82, df = 1 (11 24 35 19	5.1% 19.9%	0.36 [0.13, 0.98]	-		Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect. 2.5.2 6 months		40 = 0.01)	21	40	11.8%	0.43 (0.22, 0.82)	•	
ak2011 stotal (95% CI) al events erogeneity: Tau ^s = 0 t for overall effect: 2 2 ≥ 8001U/d	.31; Chi ⁴ = 2 = 1.02 (P =	24 35 82, cf = 1 (0.31)	11 24 35 19 P = 0.09	5.1% 19.9% ; P = 65%	0.36 [0.13, 0.96] 0.61 [0.24, 1.58]	-		Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect: 2.5.2 6 months Arshi2014		40 = 0.01) 64	21	40	3.2%	0.43 (0.22, 0.82) 0.82 [0.23, 2.93]	÷	
ak2011 total (95% CI) al events progeneity: Tau ⁴ = 0 t for overall effect: 2 2 ≥ 8001U/d pro2014	31; Chi ⁴ = 2 = 1.02 (P =	24 35 82, df = 1 (0.31) 201	11 24 35 19 P = 0.09	5.1% 19.9% ; P = 65% 23.2%	0.36 [0.13, 0.96] 0.61 [0.24, 1.58] 0.78 [0.50, 1.22]			Subtotal (95% CI) Total events Heterogeneity: Not app Test for overall effect: 2.5.2 6 months Arshi2014 Jensen2016		40 = 0.01) 64 11	21 5 8	40 66 11	3.2% 4.8%	0.43 [0.22, 0.82] 0.82 [0.23, 2.93] 0.88 [0.49, 1.55]	÷	
ak2011 total (95% CI) al events erogeneity: Tau ² = 0 t for overall effect: 2 2 ≥ 8001U/d aro2014 stotal (95% CI)	31; Chi ⁴ = 2 = 1.02 (P = 28	24 35 82, df = 1 (0.31) 201 : 201 :	11 24 35 19 P = 0.09 97 207 207	5.1% 19.9% ; P = 65%	0.36 [0.13, 0.96] 0.61 [0.24, 1.58]	•		Subtotal (95% Cl) Total events Hetarogeneity: Not app Test for overall effect: 2.5.2 6 months Arah/2014 Jensen/2016 Majak2011		40 = 0.01) 64 11 24	21 5 8 11	40 1 66 11 1 24	3.2% 4.8% 5.1%	0.43 (0.22, 0.82) 0.82 (0.23, 2.93) 0.88 (0.48, 1.55) 0.36 (0.13, 0.96)		
ak2011 total (95% CI) al events progeneity: Tau ^a = 0 t for overall effect: 2 2 ≥ 8001U/d pro2014 total (95% CI)	31; Chi ⁴ = 2 = 1.02 (P =	24 35 82, df = 1 (0.31) 201 : 201 :	11 24 35 19 P = 0.09	5.1% 19.9% ; P = 65% 23.2%	0.36 [0.13, 0.96] 0.61 [0.24, 1.58] 0.78 [0.50, 1.22]	•		Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect: 2.5.2 6 months Arahi2014 Jensen2016 Majak2011 Rubén2017		40 = 0.01) 64 11 24 53	21 5 8 11 0	40 1 66 11 1 24 53	3.2% 4.8% 5.1% 0.5%	0.43 [0.22, 0.82] 0.82 [0.23, 2.93] 0.88 [0.49, 1.55] 0.36 [0.13, 0.96] 3.60 [0.12, 72.62]		
uk2011 total (95% CI) il events progeneity: Tau* = 0 for overall effect: 2 2 ≥ 8001U/d tro2014 total (95% CI) d events	(31; Chi ⁴ = 2 = 1.02 (P = 28 28	24 35 82, df = 1 (0.31) 201 : 201 :	11 24 35 19 P = 0.09 97 207 207	5.1% 19.9% ; P = 65% 23.2%	0.36 [0.13, 0.96] 0.61 [0.24, 1.58] 0.78 [0.50, 1.22]	*		Subtotal (95% Cl) Total events Hetarogeneity: Not app Test for overall effect: 2.5.2 6 months Arah/2014 Jensen/2016 Majak2011		40 = 0.01) 64 11 24	21 5 8 11 0	40 1 66 11 1 24 53	3.2% 4.8% 5.1%	0.43 (0.22, 0.82) 0.82 (0.23, 2.93) 0.88 (0.48, 1.55) 0.36 (0.13, 0.96)		
ak2011 total (95% CI) II events regeneity: Tau* = 0 It for overall effect: 2 2 ≥ 8001U/d tro2014 total (95% CI) II events erogeneity: Not app	(31; Chi ⁴ = 2 = 1.02 (P = 28 28 icable	24 35 (82, df = 1 (0.31) 201 201	11 24 35 19 P = 0.09 97 207 207	5.1% 19.9% ; P = 65% 23.2%	0.36 [0.13, 0.96] 0.61 [0.24, 1.58] 0.78 [0.50, 1.22]	•		Subtotal (95% CI) Total events Heterogeneity: Not ap Test for overall effect: 2.5.2 6 months Arahi2014 Jensen2016 Majak2011 Rubén2017		40 = 0.01) 64 11 24 53	21 5 8 11 0	40 1 66 11 1 24 53	3.2% 4.8% 5.1% 0.5%	0.43 [0.22, 0.82] 0.82 [0.23, 2.93] 0.88 [0.49, 1.55] 0.36 [0.13, 0.96] 3.60 [0.12, 72.62]		
ak2011 total (95% CI) II events regeneity: Tau* = 0 It for overall effect: 2 2 ≥ 8001U/d tro2014 total (95% CI) II events erogeneity: Not app	(31; Chi ⁴ = 2 = 1.02 (P = 28 28 icable	24 35 (82, df = 1 (0.31) 201 201	11 24 35 19 P = 0.09 97 207 207	5.1% 19.9% ; P = 65% 23.2%	0.36 [0.13, 0.96] 0.61 [0.24, 1.58] 0.78 [0.50, 1.22]	•		Subtotal (95% CI) Total events Hetarogenety: Not ap Test for overall effect: 2.5.2 6 months Anal/2014 Jenson2016 Majak2011 Rubén2017 Subtotal (95% CI) Total events	Z = 2.57 (P 4 7 4 1	40 = 0.01) 64 11 24 53 152	21 5 8 11 0 24	40 66 11 1 24 53 54 2	3.2% 4.8% 5.1% 0.5% 23.6%	0.43 [0.22, 0.82] 0.82 [0.23, 2.93] 0.88 [0.49, 1.55] 0.36 [0.13, 0.96] 3.60 [0.12, 72.62]		
ak2011 total (95% Cf) arogeneity: Tau* = 0 for overall effect: 2 2 ≥ 8001U/d tru2014 total (95% Cf) a events arogeneity: Not appi t for overall effect: 2	(31; Chi ⁴ = 2 = 1.02 (P = 28 28 icable = 1.06 (P =	24 35 (82, df = 1 (0.31) 201 201	11 24 35 19 P = 0.09 97 207 207	5.1% 19.9% ; P = 65% 23.2%	0.36 [0.13, 0.96] 0.61 [0.24, 1.58] 0.78 [0.50, 1.22]			Subtotal (95% CI) Total events Histarogeneity: Not api Test for overall effect: 2.5.2 6 months Arshi2014 Jersen2016 Maji42011 Rubén2017 Subtotal (95% CI) Total events Histerogeneity: Tauf =	Z = 2.57 (P 4 7 4 1 0.02; Ch ² =	40 = 0.01) 64 11 24 53 152 3.20, df	21 5 8 11 0 24	40 66 11 1 24 53 54 2	3.2% 4.8% 5.1% 0.5% 23.6%	0.43 [0.22, 0.82] 0.82 [0.23, 2.93] 0.88 [0.49, 1.55] 0.36 [0.13, 0.96] 3.60 [0.12, 72.62]		
ak2011 total (95% CI) a overts propeneity: Tau* = 0 t for overall effect: 2 2 ≥ 8001U/d total (95% CI) a overts progenety: Not appi t for overall effect: 2 3 Intermittant high	(31; Chi ⁴ = 2 = 1.02 (P = 28 28 icable = 1.06 (P =	24 35 .82, df = 1 (0.31) 201 201 : 	11 24 35 19 P = 0.09 87 207 207	5.1% 19.9% ; P = 65% 23.2% 23.2%	0.36 [0.13, 0.96] 0.61 [0.24, 1.58] 0.78 [0.50, 1.22] 0.78 [0.50, 1.22]			Subtotal (95% CI) Total events Hetarogenety: Not ap Test for overall effect: 2.5.2 6 months Anal/2014 Jenson2016 Majak2011 Rubén2017 Subtotal (95% CI) Total events	Z = 2.57 (P 4 7 4 1 0.02; Ch ² =	40 = 0.01) 64 11 24 53 152 3.20, df	21 5 8 11 0 24	40 66 11 1 24 53 54 2	3.2% 4.8% 5.1% 0.5% 23.6%	0.43 [0.22, 0.82] 0.82 [0.23, 2.93] 0.88 [0.49, 1.55] 0.36 [0.13, 0.96] 3.60 [0.12, 72.62]		
ak2011 total (05% CI) al events erogeneity: Tau* = 0 tor overall effect: 2 2 ≫ 800LU/d aru2014 2 ≫ 800LU/d aru2014 aru2014 al events erogeneity: Not appi tor overall effect: 2 3 Intermittent high N2014	131; Chi ⁴ = 2 = 1.02 (P = 28 28 icable = 1.06 (P = -dose 4	24 35 .82, df = 1 (0.31) 201 .201	11 24 35 19 P = 0.09 37 207 37 37 5 66	5.1% 19.9% ; # = 65% 23.2% 23.2%	0.36 [0.13, 0.96] 0.61 [0.24, 1.58] 0.78 [0.50, 1.22] 0.78 [0.50, 1.22] 0.82 [0.23, 2.93]			Subtotal (19% CI) Total events Hetarogeneity: Not ap Test for overall effect. 2.5.2 6 months Arsh2014 Jersen2016 Maji42011 Rubén2017 Subtotal (19% CI) Total events Heterogeneity: Tau* = Test for overall effect.	Z = 2.57 (P 4 7 4 1 0.02; Ch ² =	40 = 0.01) 64 11 24 53 152 3.20, df	21 5 8 11 0 24	40 66 11 1 24 53 54 2	3.2% 4.8% 5.1% 0.5% 23.6%	0.43 [0.22, 0.82] 0.82 [0.23, 2.93] 0.88 [0.49, 1.55] 0.36 [0.13, 0.96] 3.60 [0.12, 72.62]	÷	
ak2011 stotal (35% CI) al events arrogeneity: T au ⁴ = 0 t for overall effect: 2 2 \ge 8000LU/d aro2014 stotal (35% CI) al events arcogeneity: Not appi t for overall effect: 2 3 intermitiant high hi2014 firesu2015	131; Chi ⁴ = 2 = 1.02 (P = 28 28 icable = 1.06 (P = -dose 4	24 35 82, df = 1 (0.31) 201 201 201 201 201 201 201 201 201 201	11 24 35 19 P = 0.09 37 207 207 37 5 66 51 125	5.1% 19.5% ; P = 65% 23.2% 23.2% 3.2% 41.3%	0.36 [0.13, 0.96] 0.61 [0.24, 1.58] 0.78 [0.50, 1.22] 0.78 [0.50, 1.22] 0.82 [0.23, 2.93] 0.82 [0.60, 1.14]			Subtotal (95% CI) Total events Heterogeneity: Not app Test for overall effect. 2.5.2 6 monthe Annh2014 Jensen2016 Majak2011 Rubbna017 Subtotal (95% CI) Total events Heterogeneity: Tau* = Test for overall effect: 2.5.3 > 12 months	Z = 2.57 (P 4 1 16 0.02; Ch ² = Z = 1.24 (P	40 = 0.01) 64 11 24 53 152 • 3.20, df = 0.21)	21 5 8 11 0 1 24 •3 (P = 0.	40 11 24 53 54 36); P	3.2% 4.8% 5.1% 0.5% 3.6%	0.43 [0.22, 0.82] 0.82 [0.23, 2.93] 0.85 [0.44, 1.56] 0.36 [0.13, 0.96] 3.00 [0.12, 72 02] 0.73 [0.45, 1.20]		
ak2011 total (195% CI) al events encigeneity: Tau* = 0 to cverrall affect: 2 2 ≥ 850LUid encigeneity: Not appi t for overall effect: 2 3 Intermittent high hi2014 fineau2015 hierma 2017	131; Chi ⁴ = 2 = 1.02 (P = 28 28 icable = 1.06 (P = -dose 4	24 35 82, df = 1 (0.31) 201 201 201 201 201 201 201 201 201 201	11 24 35 19 9 P = 0.09 37 207 37 5 66 51 125 21 40	5.1% 19.9% ; # = 65% 23.2% 23.2% 3.2% 41.3% 11.8%	0.36 [0.3, 0.96] 0.61 [0.24, 1.58] 0.78 [0.50, 1.22] 0.78 [0.50, 1.22] 0.82 [0.23, 2.93] 0.82 [0.60, 1.14]	•		Subtotal (85% CI) Total events Hetaropsnety: Not ag Test for overall effect: 2.5.2 6 months Anhi2014 Jensen2016 Maja22011 Rubbca[195% CI) Total events Heterogenesity: Tau [#] = Test for overall effect: 2.5.3 > 12 months Castro2014	Z = 2.57 (P 4 7 4 1 0.02; Chi ² = Z = 1.24 (P 28	40 = 0.01) 64 11 24 53 152 • 3.20, cf • = 0.21) 201	21 5 8 11 24 =3 (P = 0.	66 11 1 24 53 154 2 36): P	3.2% 4.8% 5.1% 5.5% 5.3.6% = 6%	0.43 [0.22, 0.82] 0.82 [0.23, 2.90] 0.85 [0.49, 1.55] 0.36 [0.13, 0.96] 3.00 [0,12, 72,02] 0.73 [0.45, 1.20] 0.78 [0.50, 1.22]		
k20011 total (95% CI) i events progeneity: Tau* = 0 for overall effect: 2 ≥ 8001UJd vo2014 total (95% CI) i events krogeneity: Not appi for overall effect: 2 3 Intermittent high 12014 ineau2015 harmi 2017 ér2017	131; Chi ⁴ = 2 = 1.02 (P = 28 icable = 1.06 (P = 4 42 9 1	24 35 82, df = 1 (0.31) 201 201 201 201 201 201 201 40 53	11 24 35 19 87 207 87 207 87 5 66 51 125 21 40 0 53	5.1% 19.9% ; P = 65% 23.2% 3.2% 41.3% 0.5%	0.36 [0.13, 0.96] 0.61 [0.24, 1.58] 0.78 [0.50, 1.22] 0.78 [0.50, 1.22] 0.82 [0.23, 2.93] 0.82 [0.60, 1.14] 0.43 [0.22, 0.82]			Subtotal (89% CI) Total events Haterogeneity: Not ap Test for overall effect. 2.5.2 & months Anh/2014 Junsar02016 Majak/2011 Rubin0307 Subtotal (8% CI) Total events Heterogeneity: Tau? = Test for overall effect: 2.5.3 > 12 months Castr2014 Matriceau2015	Z = 2.57 (P 4 1 16 0.02; Ch ² = Z = 1.24 (P	40 = 0.01) 64 11 24 53 152 -3.20, cf - = 0.21) 201 125	21 5 8 11 0 1 24 = 3 (P = 0.	40 66 11 24 53 154 36): P 207 125 4	3.2% 3.2% 4.8% 5.1% 0.5% 3.6% = 6% 3.2% 11.3%	0.43 [0.22, 0.62] 0.82 [0.23, 2.63] 0.88 [0.44, 1.53] 0.36 [0.10, 24, 1.54] 0.30 [0.12, 72.02] 0.73 [0.45, 1.20] 0.76 [0.50, 1.22] 0.42 [0.60, 1.14]		
ix2011 total (95% CI) i events progeneity: Tau* = 0 tor overall effect: Z 2 ≥ 800000/ tor overall effect: Z 2 ≥ 800000/ tor overall effect: Z 3 intermittent high x2014 tor overall effect: Z 3 intermittent high x2014 tor overall effect: Z 3 intermittent high x2015 harraf 2017 érc2017	131; Chi ⁴ = 2 = 1.02 (P = 28 icable = 1.06 (P = 4 42 9 1	24 35 82, df = 1 (0.31) 201 201 50 201 54 40 53 282	11 24 35 19 9 P = 0.09 97 207 207 37 5 66 51 125 21 40 0 53 254	5.1% 19.9% ; # = 65% 23.2% 23.2% 3.2% 41.3% 11.8%	0.36 [0.3, 0.96] 0.61 [0.24, 1.58] 0.78 [0.50, 1.22] 0.78 [0.50, 1.22] 0.82 [0.23, 2.93] 0.82 [0.60, 1.14]			Subtotal (8% Cr) Total oversit Heteropenety: Not ap Test for overall effect 2.5.2 & months Arab2014 Jensen2016 Maja2011 Rober0017 Total events Heteropenety: Tar* = Test for overall effect 2.5.3 > 12 months Cash2014 Marfineau2015 Subtotal (8% Cr)	Z = 2.57 (P 4 7 4 1 16 0.02; Chi ^a = Z = 1.24 (P 28 42	40 = 0.01) 64 11 24 53 152 • 3.20, cf • = 0.21) 201	21 5 8 11 0 24 = 3 (P = 0. 37 51 3	40 66 11 24 53 154 36): P 207 125 4	3.2% 4.8% 5.1% 5.5% 5.3.6% = 6%	0.43 [0.22, 0.82] 0.82 [0.23, 2.90] 0.85 [0.49, 1.55] 0.36 [0.13, 0.96] 3.00 [0,12, 72,02] 0.73 [0.45, 1.20] 0.78 [0.50, 1.22]		
k2011 il events trogenetty: Tau* = 0 for overall effect: 2 ≥ ≥ 8001U/d tro2014 tocal (85% c1) il events tor overall effect: 2 à Intermittent high k2014 insea2015 harnal 2017 botal (85% c1) tovats	131; Chi ^a = 2 = 1.02 (P = 28 28 icable = 1.06 (P = 4 42 B 1 56	24 35 82, df = 1 (0.31) 201 201 201 30 201 40 53 282	11 24 35 19 P = 0.09 87 207 87 207 87 5 66 51 125 51 125 51 125 77	5.1% 19.9% ; # = 65% 23.2% 23.2% 41.3% 11.8% 0.5% 56.9%	0.36 [0.13, 0.96] 0.61 [0.24, 1.58] 0.78 [0.50, 1.22] 0.78 [0.50, 1.22] 0.82 [0.23, 2.93] 0.82 [0.60, 1.14] 0.43 [0.22, 0.82]			Subtotal (89% CI) Total events Hetaropanety: Not ap Test for overall effect: 2.5.2 6 months Arah2014 Juneanc2016 Majk4011 Ruben2017 Subtotal (89% CI) Total events Hetaropanety: Tau' = Total events CastV02014 Martineau2015 Subtotal (89% CI) Total events	Z = 2.57 (P 4 7 4 1 1 6 0.02; Chi ² = Z = 1.24 (P 28 42 70	40 = 0.01) 64 11 24 53 152 • 3.20, df - = 0.21) 201 125 326	21 5 8 11 0 1 24 = 3 (P = 0. 37 51 51 38	40 66 11 24 53 154 36): ¹⁴ 207 207 207 207 207 207 207 207	3.2% 4.8% 5.1% 0.5% 23.6% = 6% 13.2% 13.2%	0.43 [0.22, 0.62] 0.82 [0.23, 2.63] 0.88 [0.44, 1.53] 0.36 [0.10, 24, 1.54] 0.30 [0.12, 72.02] 0.73 [0.45, 1.20] 0.76 [0.50, 1.22] 0.42 [0.60, 1.14]	•	
pi2011 il events trogenetity: Tau* = 0 t for overall effect: Z ≥ b600UUd total (95% CI) il events rogenetity: Not appl t for overall effect: Z 3 intermittent high t2014 finesu2015 harraf 2017 ér2017 t cotal (95% CI) il events tercopretity: Tau* = 0	131; Chi* = 2 = 1.02 (P = 28 28 28 icable = 1.06 (P * 4 4 2 9 1 56 1 56 100; Chi* = 3	24 35 (82, df = 1 (0.31) 201 201 201 201 201 201 201 202 202 202	11 24 35 19 P = 0.09 87 207 87 207 87 5 66 51 125 51 125 51 125 77	5.1% 19.9% ; P = 65% 23.2% 3.2% 41.3% 0.5%	0.36 [0.13, 0.96] 0.61 [0.24, 1.58] 0.78 [0.50, 1.22] 0.78 [0.50, 1.22] 0.82 [0.23, 2.93] 0.82 [0.60, 1.14] 0.43 [0.22, 0.82]			Subtotal (8% Cr) Total oversit Heteropenety: Not ap Test for overall effect 2.5.2 & months Arab2014 Jensen2016 Maja2011 Rober0017 Total events Heteropenety: Tar* = Test for overall effect 2.5.3 > 12 months Cash2014 Marfineau2015 Subtotal (8% Cr)	Z = 2.57 (P 4 7 4 1 0.02; Chi ² = Z = 1.24 (P 28 42 70 0.00; Chi ² =	40 = 0.01) 84 11 24 53 152 3.20, df - = 0.21) 201 125 326 0.04, df -	21 5 8 11 0 1 24 = 3 (P = 0. 37 51 51 38	40 66 11 24 53 154 36): ¹⁴ 207 207 207 207 207 207 207 207	3.2% 4.8% 5.1% 0.5% 23.6% = 6% 13.2% 13.2%	0.43 [0.22, 0.62] 0.82 [0.23, 2.63] 0.88 [0.44, 1.53] 0.36 [0.10, 24, 1.54] 0.30 [0.12, 72.02] 0.73 [0.45, 1.20] 0.76 [0.50, 1.22] 0.42 [0.60, 1.14]	•	
µ2011 l events total (195% CI) l events rogenetic; Tau* = 0 for overall effect: Z ≥ 5600U/d total (195% CI) l events vozontal; Not appi for overall effect: Z 3 intermittent high r2014 finesu2015 harmal 2017 ér2017 l events total (195% CI) i events total (195% CI)	131; Chi ^a = 2 = 1.02 (P = 28 28 28 28 28 28 28 28 28 28 28 28 28	24 35 (0.31) 201 221 0.28) 64 125 53 282 (93, df = 3 (0.09)	11 24 35 19 9 P = 0.09 37 207 37 5 66 51 125 21 40 0 53 284 77 P = 0.27	5.1% 19.9% ; P = 65% 23.2% 3.2% 41.3% 11.8% 0.5% 56.9% ; P = 24%	0.36 (0.13, 0.96) 0.61 (0.24, 1.58) 0.78 (0.50, 1.22) 0.78 (0.50, 1.22) 0.82 (0.23, 2.59) 0.82 (0.21, 2.29) 0.82 (0.21,			Subtotal (85% CI) Total events Heterogenetic, Not ap Total events Test for overall events Jensen2016 Majkk2011 RubicR017 Subtotal (85% CI) Total events Heterogenetic, Tau ⁺ = Cashv2014 Marifreex2016 Marifreex2016 Subtotal (85% CI) Total events Heterogenetic, Tau ⁺ = Test for overall effect.	Z = 2.57 (P 4 7 4 1 0.02; Chi ² = Z = 1.24 (P 28 42 70 0.00; Chi ² =	40 = 0.01) 64 11 24 53 152 3.20, df = = 0.21) 201 125 326 0.04, df = = 0.11)	21 5 8 11 24 =3 (P = 0. 37 51 51 51 51 51 51 51 51 51 51 51 51 51	40 66 11 24 53 55 36): P 207 2 207 2 4 336): P 207 2 4 336): P	3.2% 4.8% 5.1% 5.5% 23.8% = 6% 3.2% 11.3% 44.5% = 0%	0.43 [0.22, 0.82] 0.82 [0.23, 2.83] 0.88 [0.44, 1.86] 0.96 [0.13, 0.98] 0.75 [0.50, 122] 0.76 [0.50, 1.22] 0.82 [0.60, 1.14] 0.81 [0.62, 1.65]		
k2011 bic2011 (15%,C) I events rogeneity: Tat' = 0 for overall effect: 2 ≥ 8601U/d vo2014 total (15%,C) 4 events index: 104 index: 104 ind	131; Chi* = 2 = 1.02 (P = 28 28 28 28 28 28 28 28 40 4 42 8 1 1 56 56 1 56 56 26 1 56 3 1 56 26 3 1 28 28 28 28 28 28 28 28 28 28 28 28 28	24 35 882, df = 1 (0.31) 201 2201 2201 2201 2201 2201 2201 220	11 24 35 19 9 P = 0.09 37 207 37 5 66 51 125 21 40 0 53 254 77 P = 0.27 526	5.1% 19.9% ; P = 65% 23.2% 3.2% 41.3% 11.8% 0.5% 56.9% ; P = 24%	0.36 [0.13, 0.96] 0.61 [0.24, 1.58] 0.78 [0.50, 1.22] 0.78 [0.50, 1.22] 0.82 [0.23, 2.93] 0.82 [0.60, 1.14] 0.43 [0.22, 0.82]	+ + + + +		Subtotal (85% CI) Total events Hearopenety: Not ap Test for overall events Majak2011 Rushc0017 Rushc0017 Rushc0017 Rushc0017 Total events Hearopenety: Tar * Test for overall effect: 2.5.3 > 12 months Gashx0014 Subtotal (85% CI) Total events Hearopenety: Tar * Subtotal (85% CI) Total events Hearopenety: Tar * Subtotal (85% CI) Total events	Z = 2.57 (P 4 7 4 1 0.02; Chi ² = Z = 1.24 (P 28 42 70 0.00; Chi ² = Z = 1.58 (P	40 = 0.01) 84 11 24 53 152 3.20, df - = 0.21) 201 125 326 0.04, df -	21 5 8 11 24 53 (P = 0. 37 51 51 51 51 51 51 51 51 51 51 51 51 51	40 66 11 24 53 154 36): ¹⁴ 207 207 207 207 207 207 207 207	3.2% 4.8% 5.1% 5.5% 23.8% = 6% 3.2% 11.3% 44.5% = 0%	0.43 [0.22, 0.62] 0.82 [0.23, 2.63] 0.88 [0.44, 1.53] 0.36 [0.10, 24, 1.54] 0.30 [0.12, 72.02] 0.73 [0.45, 1.20] 0.76 [0.50, 1.22] 0.42 [0.60, 1.14]	•	
sk2011 cotal (195% CD) II events respendity: Tau* = 0 for overall effect: Z ≥ ≥6001U/d stor2014 total (195% CD) II events stor2014 for overall effect: Z 3 Infarmitiant high stor217 stor216 stor217 stor216 stor217 stor216 stor217 stor216 stor217 stor216 stor217 stor216 stor217 stor216 stor217 stor216 stor217 stor216 stor217 stor216 stor217 stor216 stor217 stor216 stor217 stor216 stor21	131; Chi ^a = 2 = 1.02 (P = 28 28 1005(P = 4 4 2 9 1 56 56 105; Chi ² = 3 = 1.69 (P = 95	24 35 (0.31) 201 221 221 53 53 282 93, df = 3 (0.09) 518 7	11 24 13 35 19 $P = 0.09$ 17 207 207 37 5 66 51 125 21 40 0 53 7 284 77 $P = 0.27$ 526 33	5.1% 19.9% ; P = 65% 23.2% 3.2% 41.3% 11.8% 0.5% 56.9% ; P = 24% 100.0%	0.36 (0.13, 0.96) 0.61 (0.24, 1.58) 0.78 (0.50, 1.22) 0.78 (0.50, 1.22) 0.82 (0.23, 2.59) 0.82 (0.21, 2.29) 0.82 (0.21,	•		Subtotal (85% CI) Total events Heterogenetic, Not ap Total events Test for overall events Jensen2016 Majuk2011 RubicR017 Subtotal (85% CI) Total events Heterogenetic, Tau ² = Total events Heterogenetic, Tau ² = Total events	Z = 2.57 (P 4 7 4 1 16 0.02; Chr ² = Z = 1.24 (P 28 42 70,00; Chr ² = Z = 1.58 (P 95	40 = 0.01) 84 53 152 • 3.20, cf • = 0.21) 201 125 326 • 0.04, cf • = 0.11) 518	21 5 8 11 24 = 3 (P = 0. 37 51 51 3 88 = 1 (P = 0.	40 66 11 1 24 53 54 53 54 53 54 53 54 53 53 54 53 53 53 53 53 53 53 53 53 53	3.2% 4.8% 5.1% 0.5% 33.2% 11.3% 54.5% = 0%	0.43 [0.22, 0.82] 0.82 [0.23, 2.83] 0.88 [0.44, 1.86] 0.96 [0.13, 0.98] 0.75 [0.50, 122] 0.76 [0.50, 1.22] 0.82 [0.60, 1.14] 0.81 [0.62, 1.65]		
ak2011 stotal (35% CI) al events arrogeneity: T au ⁴ = 0 t for overall effect: 2 2 \ge 8000LU/d aro2014 stotal (35% CI) al events arcogeneity: Not appi t for overall effect: 2 3 intermitiant high hi2014 firesu2015	131; Chi ^a = 2 = 1.02 (P = 28 28 1005(P = 4 4 2 9 1 56 56 105; Chi ² = 3 = 1.69 (P = 95	24 35 (0.31) 201 221 221 53 53 282 93, df = 3 (0.09) 518 7	11 24 13 35 19 $P = 0.09$ 17 207 207 37 5 66 51 125 21 40 0 53 7 284 77 $P = 0.27$ 526 33	5.1% 19.9% ; P = 65% 23.2% 3.2% 41.3% 11.8% 0.5% 56.9% ; P = 24% 100.0%	0.36 (0.13, 0.96) 0.61 (0.24, 1.58) 0.78 (0.50, 1.22) 0.78 (0.50, 1.22) 0.82 (0.23, 2.90) 0.82 (0.23, 2.90) 0.82 (0.52, 1.22) 0.82 (0.52, 1.52) 0.82 (0.52, 1.52) 0.82 (0.52, 1.52) 0.78 (0.56, 0.82)		10 100	Subtotal (85% CI) Total events Hearopenety: Not ap Test for overall events Majak2011 Rushc0017 Rushc0017 Rushc0017 Rushc0017 Total events Hearopenety: Tar * Test for overall effect: 2.5.3 > 12 months Gashx0014 Subtotal (85% CI) Total events Hearopenety: Tar * Subtotal (85% CI) Total events Hearopenety: Tar * Subtotal (85% CI) Total events	Z = 2.57 (P 4 7 4 1 16 0.02; Chr ² = Z = 1.24 (P 28 42 70,00; Chr ² = Z = 1.58 (P 95	40 = 0.01) 84 53 152 • 3.20, cf • = 0.21) 201 125 326 • 0.04, cf • = 0.11) 518	21 5 8 11 24 = 3 (P = 0. 37 51 51 3 88 = 1 (P = 0.	40 66 11 1 24 53 54 53 54 53 54 53 54 53 53 54 53 53 53 53 53 53 53 53 53 53	3.2% 4.8% 5.1% 0.5% 33.2% 11.3% 54.5% = 0%	0.43 [0.22, 0.82] 0.82 [0.23, 2.93] 0.86 [0.44, 1.80] 0.36 [0.13, 0.96] 0.73 [0.46, 1.20] 0.73 [0.50, 1.22] 0.76 [0.50, 1.22] 0.87 [0.60, 1.14] 0.81 [0.62, 1.65] 0.73 [0.56, 0.92]		+

Highlights

Vitamin D may be an adjunct therapy for a certain group of patients with asthma. We evaluated the influence of baseline vitamin D status on asthma-related outcomes. Treatment effect was found in patients with air limitation and vitamin D insufficiency. More RCTs are required to evaluate the identical dose and duration of vitamin D.

Conflict of interest statement

We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence the work submitted, there is no professional or other personal interest of any nature or kind in any product, service and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled, "Association between vitamin D status and asthma control: a meta-analysis of randomized trials".